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SUMMARY 
Vectors based on adeno-associated virus type 2 (AAV) offer considerable promise for 
somatic gene therapy of various diseases (e.g. cystic fibrosis, hemophilia B, cancer). 
Limitations, however, still exist and require further improvement. The study presented here 
addresses two major problems that hamper a widespread use of AAV in human gene therapy: 
First, the loss of site-specific integration of recombinant AAV vectors (rAAV) due to the 
deletion of the rep gene, and secondly, the potential neutralization of AAV gene therapy 
vectors by preexisting antibodies. 
A unique advantage of wild-type AAV (wtAAV) is the ability to integrate into the 
host genome at a specific site within the human chromosome 19 (AAVS1), especially with 
regard to stable transgene expression and avoiding the risk of insertional mutagenesis by 
random integration. Site-specific integration depends on the presence of the viral rep gene. 
Currently available rAAV vectors are devoid of all viral genes and therefore do not target 
AAVS1. In order to define whether targeted integration of a rAAV vector can be restored by 
providing the rep gene in trans, HeLa cells were transfected with a plasmid expressing Rep 
under control of its natural promoter followed by transduction with a rAAV vector, and 
analyzed for site-specific integration of the transgene cassette. Similar to wtAAV in these 
experiments, 70% of the analyzed cell clones exhibited site-specific integration of the ITR 
flanked transgene cassette into chromosome 19 without adverse effects on the cells, while 
control transduction with rAAV alone resulted in random integration. This demonstrated that 
site-specific integration of a transgene encoding rAAV vector can be efficiently restored by 
providing the rep gene in trans. 
Based on these findings a rAAV vector was developed where a plasmid coding for 
Rep was coupled as polylysine/DNA complex (PLL/DNA) directly to the capsid of the virion 
which would allow for targeted integration of rAAV. Plasmid DNA of various sizes could be 
complexed by polylysine to small compact particles and efficiently coupled to the AAV 
capsid via a biotin-streptavidin bridge. Biotinylation of AAV as well as conjugation of 
streptavidin did not interfere with the viral infection process. Furthermore, co-transduction of 
a PLL/DNA complex coupled to the AAV capsid was demonstrated by single virus tracing 
and FACS analysis, thus providing the basis for the generation of specifically integrating 
rAAV vectors. 
Another limitation for the in vivo application of AAV vectors is the high prevalence of 
human serum antibodies against the AAV capsid. In particular neutralizing antibodies 
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represent a severe problem as they can reduce or even eliminate transgene expression of the 
delivered vector. To characterize immunogenic domains of the AAV capsid and to develop 
strategies to circumvent neutralization by antibodies, six AAV capsid mutants carrying 
peptide insertions in surface exposed loop regions were investigated in binding and 
neutralization assays. Mutations at position 534 and 573 reduced the affinity of human 
antisera in the majority of the analyzed serum samples, indicating that these capsid domains 
might be preferentially recognized by the human antibodies. Additionally, AAV vectors 
carrying two different targeting peptides inserted in position 587 escaped neutralization by 
human antibodies without losing their ability to infect cells via the targeted receptors. These 
data suggest that some major disadvantages of neutralizing antibodies might be overcome by 
an AAV retargeting vector modified at position 587.  
Taken together, these results should be useful for the design of an improved 
generation of rAAV vectors: Providing rep-DNA as PLL/DNA should allow rAAV vectors to 
integrate specifically at chromosome 19. Furthermore, capsid modifications could help to 
overcome binding and neutralization by human antisera in clinical gene therapy applications. 
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1 Human Gene Therapy: A Short Overview 
Human gene therapy is a very young discipline when compared to other medical sciences. It 
can be broadly defined as the transfer of genetic material to cure a disease or at least to 
improve the clinical status of a patient. Key findings in molecular biology which have 
provided the basis for gene therapy, identification of the DNA structure and genetic code and 
lately the sequencing of the human genome, have been accomplished only within the last five 
decades. A milestone in experimental medicine was the first phase I gene-based clinical trial 
in 1990 which dealt with the treatment of adenosine deaminase deficiency (Blaese et al. 
1995). The initial success of this clinical trial gave rise to the submission of many other 
human gene therapy protocols. Over the last decade, more than 600 phase I and phase II gene-
based clinical trials have been conducted worldwide for the treatment of cancer and inherited 
or acquired genetic disorders. Recently, these trials have also been extended to the treatment 
of other diseases like AIDS and cardiovascular diseases. Presently available gene delivery 
vehicles for somatic gene transfer can be broadly divided into two categories: viral and 
nonviral vectors (Table 1). Based on the nature of their genome, viral vectors can be divided 
into RNA (retroviruses) and DNA (adeno-associated virus, adenovirus, herpes simplex virus, 
pox virus) viral vectors. Viruses are intracellular parasites that have developed efficient 
strategies to invade host cells, and in most cases, transport their genetic information into the 
nucleus. The major advantages of viral vectors are their high transduction efficiency and the 
potential stable expression of the therapeutic gene (retroviruses, adeno-associated virus). A 
limitation, however, is the risk of toxicity of the vector and induction of immunological 
reactions against the vector or its transgene (e.g. adenoviral vectors). The nonviral vectors, 
also known as synthetic gene delivery systems, represent the second category of delivery 
vehicles and rely on direct delivery of either naked DNA or RNA with cationic lipids. 
Nonviral vectors do not share the safety risks of the viral transfer systems, but suffer from low 
efficiency of gene transfer and only transient expression of the delivered genes. Although 
distinct classes of vectors have different combinations of favorable features, the ideal vector 
system has not yet been found. Constant investigations, however, will further improve the 
existing vector systems and many disadvantages can be overcome.  
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Table 1. Gene therapy clinical trials worldwide (www.wiley.co.uk/genmed/clinical/) 
Vector     Trials1 Example of diseases  pros / cons 
Viral     
Adeno-associated 
virus (AAV)   15   (2.4%) 
Cystic fibrosis, hemophilia B 
prostate cancer, neurological 
disorders, muscular dystrophy 
Adenovirus 171   (26.9%) 
Many cancers, peripheral 
artery disease, cystic fibrosis, 
Canavan disease 
Herpes simplex 
virus (HSV)     5   (0.8%) Brain tumor, colon carcinoma 
Pox virus   39   (6.1%) Many cancers 
Retrovirus 217   (34.1%) 
Many cancers, AIDS, SCID, 
rheumatoid arthritis, graft-
versus-host disease, multiple 
sclerosis, osteodysplasia, 
hemophilia 
+  high efficiency, stable 
gene expression 
(AAV, retroviruses) 
 
!  low selectivity, risk of 
immunogenicity or 
toxicity, limited coding 
capacity (except HSV)
Nonviral     
Gene gun2     5   (0.8%) Melanoma, sarcoma 
Lipofection3   77   (12.1%) 
Many cancers, cystic fibrosis, 
coronary artery disease, 
restenosis 
Naked DNA 
(plasmid)   70   (11.0%) 
Many cancers, peripheral 
artery disease, coronary artery 
disease, peripheral 
neuropathy, open bone 
fractures 
RNA transfer     6   (0.9%) Many cancers 
+  high safety, unlimited 
coding capacity 
 
!  low efficiency, low 
selectivity, transient 
gene expression 
Other   25   (3.9%)   
1 Number of open clinical trials world wide  
2 DNA coated on small gold particles and shot with a special gun into target tissue 
3 Includes liposomes and various packages of lipid, polymer, and other molecules 
 
2 Adeno-Associated Virus 
Adeno-associated virus (AAV) is a particularly promising delivery system for gene therapy. 
In 1994 the first clinical trial was conducted with this vector system dealing with cystic 
fibrosis (Flotte & Carter 1995). AAV is a member of the parvovirus family. Viruses of this 
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family have a single-stranded DNA genome of approximately 5 kb and a non-enveloped 
icosahedral capsid. With a diameter of only 18 to 30 nm the parvoviruses are among the 
smallest known viruses. The family Parvoviridae includes two subfamilies: the Parvovirinae, 
which infect vertebrates, and the Densovirinae, which infect insects. Each of the subfamilies 
includes three genera. Adeno-associated viruses belong to the Dependovirus genus. In 
contrast to members of the Parvovirus genus (e.g. canine parvovirus, porcine parvovirus, 
Aleutian mink disease virus) and the Erythrovirus genus (human parvovirus B19), which are 
autonomous parvoviruses, adeno-associated viruses naturally depend on co-infection of an 
unrelated helper virus, e.g. adenovirus (Ad), herpesvirus (HSV), human cytomegalovirus, or 
papillomavirus, for productive infection (for review see Muzyczka & Berns 2001). Originally, 
the first serotype of AAV, AAV type 2, was found as a contaminant in laboratory stocks of 
adenovirus, hence the name “adeno-associated virus” (Atchison et al. 1965; Hoggan et al. 
1966). Up to now eight serotypes (AAV type 1 – AAV type 8), which share different levels of 
sequence homology, have been identified. Although the other serotypes have attracted 
increasing attention during recent years, AAV type 2 is the most prominent serotype for gene 
therapy, being the first isolated, cloned, and best characterized. Since all following 
descriptions will refer to AAV type 2, it will be termed AAV throughout this chapter.  
The life cycle of AAV has two distinct intracellular phases (Fig. 1). In the absence of 
co-infection by a helper virus the latent cycle is initiated. AAV enters the cell, and after a 
limited expression of viral regulatory proteins (Rep proteins), the virion integrates into the 
host genome in the q arm of chromosome 19 at a specific locus (AAVS1). After super-
infection with a helper virus, the integrated genome is activated by entering the lytic cycle, 
leading to viral gene expression, rescue and replication of the AAV genome with subsequent 
production of viral progeny (Berns & Giraud 1996). Besides helper virus also genotoxic 
agents (e.g. UV-irradiation, γ-irradiation, hydroxyurea, topoisomerase inhibitors, and various 
chemical carcinogens) can support a productive infection (Heilbronn et al. 1985; Russell et al. 
1995; Yakobson et al. 1989; Yalkinoglu et al. 1991; Yalklinoglu et al. 1988). These 
observations led to the conclusion that the role of helper functions is rather the induction of 
the appropriate cellular milieu (expression of stress response genes) required for AAV DNA 
replication than direct involvement of helper virus gene products (Yakobson et al. 1987).  
The natural route for AAV infections is assumed to occur via the respiratory or 
gastrointestinal route as is the case for Ad, because in vivo AAV has been typically found as a 
contaminant of Ad isolates (Blacklow et al. 1971). However, it is not yet clear what tissue or 
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organ is a preferred site of latency in humans. Nevertheless, recombinant AAV vectors have 
demonstrated infection and long-term gene expression in a wide variety of tissues, including 
brain, liver, muscle, lung, and retina in animals (Fisher et al. 1997; Flannery et al. 1997; 
Flotte et al. 1993; Kaplitt et al. 1994; Snyder et al. 1997; Xiao et al. 1996). Although AAV is 
widespread, no disease has been associated with the virus (Berns & Linden 1995). On the 
contrary, AAV seems to be protective against bovine papillomavirus and Ad mediated 
cellular transformation (de la Maza & Carter 1981; Hermonat 1989; Khleif et al. 1991; Mayor 
et al. 1973), and to have cytotoxic effects in malignant cells (Raj et al. 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The biphasic life cycle of AAV. In the presence of a helper virus, adenovirus or herpesvirus, AAV 
enters the lytic cycle and undergoes a productive infection. Lacking a helper virus the AAV DNA can stably 
integrate preferentially into chromosome 19 of the host genome (AAVS1). After super-infection with a helper 
virus AAV can be rescued from the latent state and reenter the lytic cycle. 
infectionLatent Cycle
ch 19
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2.1 Genomic Organization of AAV 
The wild-type AAV (wtAAV) has a single-stranded DNA genome of 4680 nucleotides. Two 
large open reading frames (ORF) occupy the right and the left half of the genome, 
respectively. These ORF are flanked by palindromic sequences, the inverted terminal repeats 
(Fig. 2). 
¾ The 145 nucleotide long inverted terminal repeats (ITR) form a T-shaped structure on 
either side of the symmetry axis. The ITRs contain a Rep binding site (RBS) and a 
specific cleavage site for the bound Rep protein (terminal resolution site, TRS) (Im & 
Muzyczka 1990; McCarty et al. 1994; Snyder et al. 1993; Snyder et al. 1990). They 
constitute an important cis-acting signal which serves as origin of replication (ori) and 
primer for initiation of DNA synthesis. Furthermore they are critical for regulation of 
gene expression, and essential for site-specific integration of AAV and rescue of the viral 
genome from the integrated state (Labow & Berns 1988; McLaughlin et al. 1988; 
Samulski et al. 1987). 
¾ The 5’-ORF rep encodes the non-structural, regulatory Rep proteins. Two promoters, p5 
and p19, direct expression of the rep gene. A common intron results in the production of 
four Rep proteins: p5 initiated Rep78, Rep68 and p19 initiated Rep52, Rep40. Rep78 and 
Rep68 are multifunctional proteins with diverse biochemical activities, including DNA 
binding, DNA ligase, ATPase, DNA helicase, and strand-specific, site-specific 
endonuclease activities (Im & Muzyczka 1990; Im & Muzyczka 1992; Smith & Kotin 
2000; Zhou et al. 1999). They are involved in AAV DNA replication, transcriptional 
control and targeted integration. The two smaller proteins, Rep52 and Rep40, appear to 
be involved directly in the accumulation and encapsidation of single-stranded genomes 
into preformed capsids and have also been shown to possess ATPase and helicase 
activities but seem to lack DNA binding activity (Chejanovsky & Carter 1989; Dubielzig 
et al. 1999; King et al. 2001; Smith & Kotin 1998). The Rep proteins can act as both 
repressors and transactivators of AAV transcription by regulating the activities of the 
three viral promoters. In the absence of helper virus, all Rep proteins have been observed 
to repress p5 and p19 transcription (Kyostio et al. 1994).  
¾ The 3’-ORF cap encodes three structural proteins with overlapping amino acid sequence, 
VP1, VP2, and VP3, which form the viral capsid. They are all transcribed from the p40 
promoter and expressed in a ratio of approximately 1:1:8 (Kronenberg et al. 2001). The 
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different translation efficiency is a consequence of differential splicing of the intron for 
synthesis of VP1, and the use of an unusual initiator codon (ACG) for VP2 synthesis. 
VP3 is translated from the initiator codon AUG and is the major capsid protein (Becerra 
et al. 1988; Becerra et al. 1985). All three capsid proteins use a common stop codon. The 
molecular weight of VP1, VP2, and VP3 is 90 kDa, 72 kDa, and 60 kDa, respectively. 
VP2 and VP3 are sufficient for capsid formation, yet VP1 is required for viral infection 
(Hermonat et al. 1984; Smuda & Carter 1991; Tratschin et al. 1984). The N-terminus of 
VP2 contains a nuclear localization signal which is required for translocation of VP3 to 
the nucleus (Hoque et al. 1999; Ruffing et al. 1992). 
The half life of the Rep and Cap proteins is 15 h, and of the AAV mRNA approx. 4 to 6 h 
(Carter & Rose 1974; Redemann et al. 1989). The AAV particle has a molecular weight 
between 5.4 and 6.0 x 106 g/mol. Approximately 70% of the mass is protein, and the 
remaining is DNA. AAV particles are very resistant to inactivation. They are stable between 
pH 3 and 9 and at 56°C for 60 min. Inactivation of the virus is possible by formalin, β-
propriolactone, hydroxylamine, and oxidizing agents (Berns et al. 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Map of the AAV genome. The AAV genome encompasses 4680 nucleotides, divided into 100 map 
units. Indicated are the two inverted terminal repeats (ITRs), the three viral promoters at map position 5, 19, and 
40 (p5, p19, and p40) and the polyadenylation signal at map position 96 (poly A). The open reading frames are 
represented by rectangles, untranslated regions by solid lines and the introns by carats. Large Rep proteins 
(Rep78 and Rep68) under the control of the p5 promoter and small Rep proteins (Rep52 and Rep40) driven by 
the p19 promoter exist in spliced and unspliced isoforms. The cap genes encoding the three different capsid 
proteins VP1, VP2, and VP3 are under control of the p40 promoter. 
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2.2 Production of AAV Vectors 
For the generation of recombinant AAV vectors (rAAV) rep and cap are deleted by removing 
96% of the genome, leaving only the ITR sequences of the parent virus, which are the solely 
required cis elements for the production of viral particles (replication and packaging). Due to 
the limited coding capacity of AAV, the removal of all viral genes is, amongst other reasons, 
required to create space for a heterologous gene, a marker gene (GFP, lacZ) or a therapeutic 
gene, which is cloned in place of the rep and cap genes between the ITRs.  
For the production of rAAV vectors two different plasmids are needed (Fig. 3A). The 
“vector plasmid” contains the transgene flanked by the viral ITRs. The two AAV-specific 
genes required in trans, rep and cap, are cloned onto a “helper plasmid” which does not carry 
the ITR sequences. These two plasmids are co-transfected together with a third plasmid 
providing the adenoviral functions necessary for AAV replication (Fig. 3B). Instead of the 
adenoviral plasmid, co-infection with wild-type Ad is also possible, but this procedure yields 
AAV preparations that are contaminated with Ad particles. After transcription and translation 
of the Rep and Cap proteins the ITR flanked transgene cassette from the vector plasmid is 
replicated, and the single-stranded DNA molecules are encapsidated into preformed AAV 
capsids (Dubielzig et al. 1999; Samulski et al. 1989). Thereafter viral particles can be 
harvested and purified, either by gradient centrifugation (CsCl, Iodixanol) and/or column 
chromatography (Zolotukhin et al. 1999). 
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A
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Figure 3. Packaging of AAV. (A) Plasmid constructs used for packaging of rAAV. In contrast to the wild-type 
AAV-plasmid, which contains the viral rep and cap gene and the ITRs, the vector plasmid is devoid of all viral 
genes. Only the ITRs are left which flank the transgene and serve as packaging signal. The helper plasmid 
provides the regulatory proteins (Rep) and the capsid proteins (Cap) required for replication of the ITR flanked 
transgene cassette and packaging into preformed capsids. (B) Packaging of AAV. Vector plasmid, helper 
plasmid, and adenoviral plasmid are transfected into 293 cells. After replication and assembly of viral particles 
cells are lysed and AAV virions are harvested and purified by iodixanol gradient centrifugation. 
 
2.3 Infection Biology of AAV 
The infection pathway of AAV is a multistep process which involves attachment of AAV to 
the cell surface, binding to the cellular receptors, internalization of the virion, intracellular 
trafficking, and transport to the nucleus where the viral genome can be replicated and, in the 
presence of helper functions, synthesis of new viral particles can take place.  
A model of the infection process is depicted in figure 4. The first step in this process is 
the interaction of AAV with its putative primary receptor heparan sulfate proteoglycan 
(HSPG) that mediates attachment of the virion to the host cell membrane (Summerford & 
Samulski 1998). Heparan sulfate proteoglycans are widely distributed on the surface of many 
cell types. This might explain the broad host tropism of AAV. Also two co-receptors have 
293 cells
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transfection
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B
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been suggested so far, αvβ5 integrin and fibroblast growth factor receptor 1 (FGFR) 
(Qing et al. 1999; Summerford et al. 1999). While αvβ5 integrin seems to be involved in 
endocytosis, FGFR is believed to additionally enhance the attachment process. Receptor 
mediated endocytosis via clathrin-coated pits seems to be the predominant, but not exclusive, 
pathway for AAV entry, at least in HeLa cells. A possible model postulates that αvβ5 integrin 
clustering facilitates the localization of virus particles to coated pits, similar to adenovirus. In 
the subsequent internalization process dynamin, a 100 kDa cytosolic GTPase, is involved 
(Bartlett et al. 2000; Duan et al. 1999; Wang et al. 1998). Specifically, oligomerization of 
dynamin into a ring structure is required for the formation of clathrin coated vesicles and 
subsequent pinching of coated pits from the cell membrane (Hinshaw & Schmid 1995; Sever 
et al. 2000). Additionally, integrin clustering has been shown to activate Rac1, a GTP binding 
protein, which facilitates internalization. Subsequently, activation of Rac1 leads to activation 
of PI3K signaling pathways (PI3K, phosphatidylinositol-3 kinase) which are required for 
efficient trafficking of endosomal vesicles containing virus along microfilaments and 
microtubules to the nucleus (Sanlioglu et al. 2000).  
In contrast to its natural helper virus, adenovirus, AAV particles seem to be delivered 
to the late endosome before they are released into the cytoplasm (Douar et al. 2001). The 
maturation of endosomes involves a progressive decrease of their internal pH. This acidic 
milieu may trigger conformational changes of the viral capsid, exposing domains which 
disrupt the endosomal membrane. Interestingly, the unique region of the AAV VP1 protein 
contains a phospholipase A2 (PLA2) motif (HDXXY) which is conserved among parvoviruses 
(Girod et al. 2002; Zadori et al. 2001). It can be speculated that externalization of this domain 
would expose the PLA2 group together with other functions located in the VP1 unique region 
(DNA binding, nuclear localization) which may be required for endosome exit and transfer of 
the viral genome to the nucleus. Notably, a significant proportion of viral particles can be 
degraded by the proteasome before they reach the nuclear compartment (Douar et al. 2001).  
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Figure 4. The AAV infection pathway. After binding to its primary attachment receptor HSPG and co-
receptors FGFR and αvβ5 integrin AAV is internalized by receptor-mediated endocytosis in a dynamin 
dependent manner into clathrin coated pits. This internalization is facilitated by the action of Rac1. Activation of 
Rac1 subsequently stimulates PI3K pathways which regulate endosome trafficking along the cytoskeleton. After 
transition to the late endosomal compartment AAV is released into the cytoplasm and enters the nucleus by an 
unknown mechanism.   
 
Relatively little is known about how the virus enters the nucleus and where viral 
uncoating occurs. Several studies have observed a perinuclear accumulation and subsequent 
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slow nuclear entry of fluorescent labeled viral particles (Bartlett et al. 2000; Sanlioglu et al. 
2000). In contrast, Seisenberger and coworkers (2001) observed by single molecule imaging a 
very quick transfer of viral particles, within minutes, to the nuclear area. Whether viral 
particles localized in the nucleus are partially uncoated or otherwise modified remains unclear 
in all studies. However, all cellular factors required for uncoating and second-strand synthesis 
are contained within the nucleus and transport across the nuclear envelope itself seems not to 
depend on active transport through nuclear pore complexes (NPC) (Hansen et al. 2001).  
In the course of a productive infection, replication of the AAV genome proceeds via a 
self-priming strand displacement mechanism in which the two large Rep proteins, Rep78 and 
Rep68, play an essential role (for review see Muzyczka & Berns 2001). At early stages of 
virus production, capsid assembly and viral DNA replication are found at distinct sites within 
the cell nucleus. Assembly of empty capsids seems to take place in the nucleolus, whereas 
DNA replication and the subsequent encapsidation of the viral genome takes place in the 
nucleoplasm (Wistuba et al. 1997; Wistuba et al. 1995). During this assembly process, first 
complexes are formed between empty capsids and large Rep-bound AAV genomes mediated 
by the interaction of large and small Rep proteins with one another and empty capsids 
(Dubielzig et al. 1999). Then helicase activity of capsid-immobilized Rep52 and Rep40 drives 
the translocation of single-stranded AAV genomes into the preformed capsids (King et al. 
2001). Both positive and negative strands of the viral genome are separately encapsidated in 
AAV virions (Mayor et al. 1969).  
 
2.4 The Structure of the AAV Capsid 
Recently the atomic structure of AAV has been determined to 3 Å resolution by x-ray 
crystallography (Xie et al. 2002) (Fig. 5). It was the first structure of a dependovirus to be 
determined. While the atomic structures of related autonomous parvoviruses, including canine 
parvovirus (CPV), feline panleukopenia virus (FPV), minute virus of mice (MVM), Aleutian 
mink disease virus (ADV), and the human parvovirus B19, have been resolved during the past 
decade, the three-dimensional structure of the AAV capsid remained unknown (Agbandje et 
al. 1994; Agbandje-McKenna et al. 1998; Chang et al. 1992; Chapman & Rossmann 1993; 
Chipman et al. 1996; McKenna et al. 1999; Strassheim et al. 1994; Tsao et al. 1991). Instead, 
alignments of these related parvoviruses with AAV had led to hypothetical models of the 
AAV capsid. Random and systematic mutagenesis approaches helped to identify functional 
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sites on the capsid, including putative binding sites for the primary receptor HSPG, 
immunogenic epitopes and flexible loop regions at the capsid surface that accept the insertion 
of targeting ligands (Girod et al. 1999; Rabinowitz et al. 1999; Wobus et al. 2000; Wu et al. 
2000). Now that the three-dimensional structure has been resolved, function can be mapped to 
the structure.  
Striking similarities but also notable differences exist between AAV and related 
autonomous parvoviruses. Each viral capsid is composed of 60 subunits arranged with T=1 
icosahedral symmetry (Xie et al. 2002). The three structural proteins VP1, VP2, and VP3, 
which share overlapping sequences and differ only at their N-termini, build the AAV capsid 
with a relative stoichiometry of about 1:1:8 (Kronenberg et al. 2001). The central motif of 
each subunit is an anti-parallel ß-barrel which is highly conserved among parvoviruses (Fig. 
5A). This β-barrel motif forms elongated smooth lumps at the inner surface of the capsid at 
the 2-fold symmetry axis (Kronenberg et al. 2001). Between the strands of the β-barrel core 
large loop insertions are found that share only low similarity among the parvovirus family. 
These loops comprise two-thirds of the capsid structure and constitute the capsid surface 
features that interact with antibodies and cellular receptors. These surface features include a 
hollow cylinder at the 5-fold axis of symmetry which is surrounded by a circular depression 
(canyon), and a depression spanning the 2-fold axis (dimple) (Fig. 5B). The most prominent 
features of the capsid are the 3-fold-proximal peaks, which cluster around the 3-fold 
symmetry axis. The peaks are not derived from one capsid subunit protein but from the 
interaction of two adjacent subunits. The sequences that compose these structures belong to 
the GH loop (between the β-sheets G and H) which, with approximately 220 amino acids, is 
the longest loop insertion. Other interactions between loops of neighboring subunits are found 
at the 5-fold cylinder, where amino acids from the HI loop interact with residues from the BC 
and EF loop. Overall, the outside surface of AAV is positively charged with clusters of 
positive charges in the canyon, surrounding the 5-fold cylinder, and at the 3-fold symmetry 
axis. Regions of negative charges are mainly found at the top of the 5-fold cylinder and at the 
sides of the 2-fold dimple facing the 3-fold axes (Fig. 5B and C). The N-terminal unique 
regions of VP1 and VP2 could not be resolved by x-ray crystallography, because of low 
electron density. Kronenberg and coworkers (2001), who performed cryo-electron 
microscopy assumed that globular structures at the inner surface of the capsid at the 2-fold 
axes of symmetry, which are attached to the smooth lumps, represent the positions for the N-
terminal extensions of VP1 and VP2.  
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Figure 5. The structure of the AAV capsid (images taken from Xie et al. 2002). (A) Ribbon drawing of a VP3 
protein. The position of the 2-fold, 3-fold, and 5-fold axis is indicated. The β-barrel core comprising two anti-
parallel β-sheets (strands A to I) is on the inner surface of the capsid. The inter-strand loops are labeled 
according to the flanking strands. (B) Surface topology (top row) and electrostatic surface potential (bottom 
row) of the AAV capsid. Red colors indicate clusters of negative charges and blue colors indicate positive 
charges. The view is down the 2-fold symmetry axis. (C) One of the 60 triangular asymmetric subunits showing 
the surface amino acids of the capsid. The amino acids are numbered according to VP2. 
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After resolution of the crystal structure of AAV important functions obtained from 
genetic data could be mapped to the structure. At the 3-fold-proximal peaks, in the valleys 
separating the three peaks of one 3-fold axis, clusters of positive charges are located, which 
are implicated in receptor binding. Although no definitive HSPG binding motif has been 
found on the capsid surface so far, mutational analyses have identified these locations being 
involved in binding to the primary receptor HSPG (Wu et al. 2000). Especially the basic 
amino acids (aa) R487 (R350), R585 (R448), R588 (R451) and H509 (H372), which are at the 
side of the peak, seem to play a crucial role (numbers in parentheses refer to VP2 numbering) 
(Fig. 5C) (Grifman et al. 2001; Wu et al. 2000; Xie et al. 2002). Interestingly, the separation 
between these clusters at the side of the peaks is 20 Å, consistent with binding neighboring 
disaccharides of the heparan sulfate moiety. These findings are supported by the fact that the 
neutralizing monoclonal antibody C37-B which inhibits binding of AAV to the host cell has 
its epitope adjacent to these residues in the three-dimensional structure, namely between aa 
492 and 503 (corresponds to aa 355-366 in VP2 numbering) at the shoulder of a peak (Wobus 
et al. 2000). The epitope of another neutralizing antibody, A20, could also be mapped to the 
3-fold spike region. It is situated in the valley between the peaks of one 3-fold axis (Wobus et 
al. 2000). In contrast to C37-B, A20 does not block receptor binding but neutralizes AAV 
infection at a post-binding step, possibly by interfering with internalization, endosomal 
release or viral uncoating (Smith 2001). These data implicate the 3-fold proximal peaks not 
only in receptor binding, but also show their possible role in recognition by the host immune 
system. Moreover, it is supposable that other important viral functions are additionally 
located at this prominent feature. 
 
2.5 The AAV Rep Proteins and their Role in Site-Specific Integration 
Adeno-associated viruses utilize a biphasic life cycle to persist in nature. In the presence of 
helper virus, adenovirus or herpesvirus, wtAAV undergoes a productive infection. Lacking a 
helper virus, the virion latently infects by integrating into the host genome. This integration 
occurs in 70% at a specific locus in the q arm of human chromosome 19 within 19q13.4 
termed AAVS1 (Giraud et al. 1994; Kotin et al. 1992; Kotin et al. 1990; Samulski et al. 
1991). Recently this AAV integration site has been identified to lie within a muscle-specific 
DNA region of the human genome (Dutheil et al. 2000).  
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The only viral cis elements required for site-specific integration are the ITRs, or at 
least partial ITR-like sequences. The ITRs contain a Rep binding site (RBS) and a specific 
cleavage site for the large Rep proteins (TRS) which seem to play an essential role for this 
integration process (Xiao et al. 1997b). Additionally, targeted integration depends on the 
large Rep proteins, Rep78 and/or Rep68, which can be provided in trans (Balague et al. 1997; 
Huttner et al. 2003; Surosky et al. 1997). Mutational analysis of Rep78 and Rep68 indicated 
that sequence specific DNA binding, site-specific endonuclease activity, and helicase activity 
are essential for site-specific recombination (Linden et al. 1996a; Urabe et al. 1999). On the 
host chromosomal side a 33 bp region within the AAVS1 has been identified as the minimal 
requirement for the targeted integration process. Interestingly, the AAVS1 also comprises a 
RBS and an abbreviated version of the TRS which are essential to target integration to 
AAVS1 (Giraud et al. 1994; Giraud et al. 1995; Linden et al. 1996a; Linden et al. 1996b). 
Recently, a spacer sequence containing either a GCTC motif or two CTC triplets embedded in 
a pyrimidine-rich sequence has been determined to be the third requisite necessary for 
specific integration (Meneses et al. 2000). The specific combination of these three parameters 
seems to be unique to AAVS1 within the human chromosome which would explain the 
specificity of the integration process.  
The exact mechanism of the integration process, however, is still unclear. Several 
models have been proposed:  
¾ One current model for targeted integration proposes that Rep68/78 binds as a hexamer 
to the RBS motifs on the chromosomal DNA and the viral DNA and thereby positions 
the incoming infecting genome at AAVS1 (Weitzman et al. 1994). This represents a 
Rep protein mediated alignment of the recombination partners AAV and AAVS1, 
initiating the non-homologous recombination event observed. Then a nick is 
introduced by Rep68/78 at the TRS in AAVS1, and DNA synthesis is initiated 
following a single-strand displacement mechanism involving the cellular polymerase 
complex. As DNA synthesis at the AAVS1 proceeds, a series of DNA template 
switches (copy choice) links the viral DNA to the chromosomal DNA (Brister & 
Muzyczka 2000; Chiorini et al. 1996; Linden et al. 1996a; Linden et al. 1996b). This 
model has been referred to as copy-choice model.  
¾ A second, more recent model supposes a cleavage-ligation mechanism for targeted 
integration which does not imply template strand switching. Smith and colleagues 
demonstrated that the large Rep proteins not only possess sequence specific binding 
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and nicking activity but also have the ability to catalyze the ligation of single-stranded 
AAV ori DNA. They proposed that Rep68/78 may mediate recombination between an 
AAV replication intermediate, which might have been generated after limited Rep 
expression during latent infection, and the chromosomal AAVS1 locus by a strand 
cleavage and exchange mechanism (Smith & Kotin 2000).  
Very often site-specific integration seems to be accompanied by rearrangements of the viral 
genome and the AAVS1 locus (Giraud et al. 1995; Kotin & Berns 1989; Kotin et al. 1992; 
McLaughlin et al. 1988; Surosky et al. 1997). These rearrangements include deletions of 
AAV sequences and the disruption of the preintegration site. Recombination junctions are 
clustered near the RBS of the AAVS1 target locus and within the ITR or the p5 promoter in 
AAV. In most latently infected cell lines the viral DNA is integrated as head-to-tail 
concatamer (Cheung et al. 1980; Laughlin et al. 1986; McLaughlin et al. 1988), but also 
inverted tandem arrays (head-to-head, tail-to-tail) have been observed (Kotin & Berns 1989). 
For rescue of AAV from the latent state after helper virus co-infection at least one intact ITR 
is required. Interestingly, one ITR copy between integrated tandems is normally found to be 
intact after integration. Therefore rescue was only observed when AAV had integrated as 
concatamer and not after monomer integration because of substantial rearrangements and 
deletions in the ITR sequences.  
As recombinant AAV (rAAV) vectors are devoid of all viral genes, they have lost the 
ability of targeted integration. rAAV vectors can still integrate through the ITR sequences, 
but at a lower frequency and only randomly into the host genome. One challenge for human 
gene therapy is to restore the ability of targeted integration of rAAV and to design 
specifically integrating vector systems. This is especially of importance with respect to a safe 
transfer system that avoids the risk of insertional mutagenesis because of random integration 
as it is the case for retroviral vectors.  
 
2.6 Immune Response against AAV 
An obstacle for the application of AAV as a gene therapy tool is the preexisting immunity 
against the virus. Generally humoral and cellular immune responses against viral gene therapy 
vectors can limit sustained transgene expression and their potential readministration. As 
rAAVs are deleted of all viral genes, these vectors are believed to be relatively non-
immunogenic which may contribute to the prolonged expression observed after AAV 
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transduction in animal studies. However, several studies have determined a high prevalence 
of serum antibodies (Ab) against the AAV capsid in the human population. They could show 
that between 30 and 96% are positive for AAV specific Ab and 18 to 67.5% of them have 
additionally neutralizing antibodies, depending on age and ethnic group (Blacklow et al. 
1968b; Chirmule et al. 1999; Erles et al. 1999; Moskalenko et al. 2000). These neutralizing 
Ab can cause considerable problems, especially when readministration of the vector is 
required. In animal experiments, neutralizing Ab have been shown to eliminate (Fisher et al. 
1997; Xiao et al. 1996) or greatly reduce (Chirmule et al. 2000; Xiao et al. 2000) the levels of 
transgene expression after readministration of the vector. Responsible for this block of 
readministration seems to be a humoral response associated with a T-cell dependent B-cell 
activation against the virion but not the transgene as seen with other viral vectors (Chirmule 
et al. 2000; Hernandez et al. 1999). Several studies have shown that transient 
immunosuppression (anti-CD40-ligand Ab and CTLA4, anti CD4) during the first 
administration helps to prevent generation of neutralizing Ab and allows readministration of a 
rAAV vector (Chirmule et al. 1999; Halbert et al. 1998; Manning et al. 1998). Acute 
inflammation due to activation of the innate immune system, i.e. neutrophils, natural killer 
cells, macrophages, and expression of chemokines and cytokines which has been strongly 
observed for Ad does not seem to take place after AAV transduction or is only very short 
lived (Zaiss et al. 2002). Therefore, AAV vectors seem to have markedly reduced 
inflammatory properties.  
For many viral vectors, e.g. adenovirus, a strong cellular immune response against the 
vector and the delivered transgene, which can cause severe complications for the treated 
patient, has been observed, as was probably the case for Jesse Gelsinger, who died in a Phase 
I gene therapy trial after application of an adenoviral vector (for further information see 
Teichler Zallen 2000). In contrast, after in vivo gene transfer by rAAV vectors, apparently no 
evidence for a cellular immune response to the transgene product has been reported (Chirmule 
et al. 1999; Hernandez et al. 1999; Jooss et al. 1998). This may be due to the fact that rAAV 
fails to infect mature dendritic cells capable of stimulating antigen-specific T-cell responses 
and therefore presentation of neoantigen might be inefficient (Jooss et al. 1998). One study 
described in vitro transduction of immature dendritic cells by AAV which initiated 
subsequently a CD40-ligand dependent T-cell response to transduced cells (Zhang et al. 
2000). The role of such immature dendritic cells for eliciting a cellular immune response after 
AAV transduction in vivo has to be further elucidated. All these observations point towards a 
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humoral response against the AAV capsid being the major immune response in animal 
studies, while a cellular immune response to the virion or the delivered gene product is rare. 
Some exceptions, however, have been observed in animal studies. Generation of cytotoxic 
T-lymphocytes (CTL) and upregulation of major histocompatibility complex (MHC) class I 
molecules was reported after i.m. application of rAAV coding for β-galactosidase (Yuasa et 
al. 2002). In other studies a humoral and cell mediated immune response to AAV vectors 
expressing foreign viral proteins, i.e. herpes simplex virus glycoproteins or influenza virus 
hemagglutinin, and foreign secreted protein, has been described (Brockstedt et al. 1999; 
Manning et al. 1997; Sarukhan et al. 2001). However, one should note that these studies 
intended to exploit AAV for vaccination and therefore an immune response against the 
transgene was desired in these studies.  
The conflicting data presented by several studies indicate that the CTL as well as the 
humoral response to the delivered gene depends on a number of variables, including the 
nature of the transgene, the route and site of injection, the age, health and immunological 
background of the subject, the degree of contamination with helper virus proteins, and even 
the maturation state of antigen presenting cells exposed to rAAV administration. This implies 
the need for a better understanding of the immune response against AAV. Moreover, new 
strategies to circumvent neutralization by antibodies and to overcome the limitations of a 
potential humoral and cellular immune response have to be developed. 
 
3 AAV as Gene Therapy Vector: Pros and Cons 
AAV has received a significant amount of interest as a potential vector for gene therapy. 
There are a number of characteristics that contribute to the potential utility of the virus for this 
purpose.  
¾ rAAV vectors can efficiently transduce a wide variety of dividing and also non-dividing, 
terminally differentiated tissues in vivo including cells of the central nervous system, eye, 
muscle, liver, lung, and hematopoietic system (Fisher et al. 1997; Fisher-Adams et al. 
1996; Flannery et al. 1997; Flotte et al. 1993; Kaplitt et al. 1994; Snyder et al. 1997).  
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¾ The vector genome persists for extended periods (up to 2 years in muscle, brain, liver, 
and eye of rodents) with no apparent decrease in expression (McCown et al. 1996; 
Snyder et al. 1999; Xiao et al. 1996).  
¾ No inflammatory response is generated by in vivo injections of the vector which is in part 
the reason for the long term gene expression. The CTL response also appears to be lower 
than that seen with most other viral vectors, as well as the humoral immune response to 
the transgene product. This may be due in part to the absence of viral genes in the vector, 
and to the observation that AAV only inefficiently infects antigen-presenting cells like 
dendritic cells (Jooss et al. 1998).  
¾ No apparent pathogenicity has been contributed by AAV so far (Berns & Linden 1995; 
Blacklow 1988; Blacklow et al. 1968b; Blacklow et al. 1971), which argues for the safety 
of this vector system. What has to be clarified, nevertheless, is the potential germ-line 
transduction which was described after acute wtAAV infection (Burguete et al. 1999; 
Erles et al. 2001).  
¾ AAV vectors have the potential to specifically integrate into the host genome. This would 
minimize the risk of insertional mutagenesis, a problem that afflicts retroviral vectors 
(development of a leukemia-like blood disorder after treatment of X-linked severe 
combined immunodeficiency by a retroviral vector in October 2002, see Hacein-Bey-
Abina et al. 2003). Additionally, readministration of the vector would be redundant. 
Currently available rAAV vectors, however, have lost this favorable characteristic due to 
the lack of the viral rep gene.  
 
The rAAV vector system has also suffered from several disadvantages, some of which have 
now been addressed.  
¾ The broad host tropism, initially considered as an advantage, has now turned out to be a 
disadvantage. Specific and selective transduction of the target tissue is highly desirable 
for in vivo gene therapy. This is not only important because of safety aspects but would 
also help to reduce the amount of delivered virus particles. First steps towards specific re-
targeting vectors have been done but require further improvements (Bartlett et al. 1999; 
Girod et al. 1999; Nicklin et al. 2001).  
¾ The coding capacity of AAV is a limiting factor for some transgene-promoter 
combinations. The optimal size for AAV vectors lies between 4.1. and 4.9 kb (Dong et al. 
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1996). Recent publications demonstrated that this problem can be overcome by the use of 
split genes that are cloned into two separate vectors (Duan et al. 2000; Nakai et al. 2000; 
Sun et al. 2000; Yan et al. 2000). These are expressed in vivo from head-to-tail 
concatamers of the vector with the use of appropriate splice signals. Still, a drawback in 
this strategy is the requirement for double transduction of the cell with complementing 
vectors and the low transduction efficiencies.  
¾ A delayed onset of transgene expression (4 to 6 weeks after injection) has been observed 
in most animal experiments and represents a problem for acute clinical applications. 
Publications have shown that second-strand synthesis may be the rate limiting step for in 
vivo expression (Ferrari et al. 1996; Fisher et al. 1996). Furthermore, they demonstrated 
that helper virus and genotoxic stress not only help wtAAV to initiate productive 
infection, but also enhance rAAV transduction. Self-complementary rAAV vectors 
containing double-stranded replication intermediates could be a means towards 
overcoming this limitation (McCarty et al. 2001). 
¾ The high prevalence of antibodies against the viral capsid and especially neutralizing 
antibodies represents a further hurdle for in vivo gene therapy. Several groups 
demonstrated that neutralizing antibodies can reduce or even eliminate transgene 
expression, which would make a readministration but also an initial therapy in many 
cases impossible (see above). Therefore, the development of rAAV vectors with the 
potential to escape the humoral response is crucial. 
 
Despite the potential drawbacks, rAAV vectors have proven to be a useful tool for many 
applications in gene therapy, some of which will be given here as examples. Several 
publications have demonstrated efficient transduction of the brain with rAAV in animal 
models and have explored the possibility of rAAV mediated therapy of Alzheimer’s (delivery 
of GABA receptor antisense constructs) and Parkinson’s disease (delivery of enzymes for 
dopamine synthesis) (Kaplitt et al. 1994; Klein et al. 1998; Mandel et al. 1997; Xiao et al. 
1997a). Other possible applications are inherited retinopathies. Mainly two groups have 
shown efficient photoreceptor-targeted gene transfer and functional recovery of 
photoreceptors after subretinal injections of AAV vectors in transgenic rodents (Flannery et 
al. 1997; Jomary et al. 1997; Lewin et al. 1998). Skeletal muscles and liver transduction with 
rAAV have been used as platforms for the secretion of several factors which are absent or 
reduced in certain diseases, including factor IX in hemophilia B (Kay et al. 2000; Snyder et 
24 Chapter I  
al. 1999; Wang et al. 1999), leptin for therapy of genetic obesity and noninsulin-dependent 
diabetes mellitus (Murphy et al. 1997), and erythropoietin (Kessler et al. 1996; Zhou et al. 
1998). Attempts to develop gene therapy for Duchenne muscular dystrophy have been 
complicated by the enormous size of the dystrophin gene. Harper et al. (2002) recently 
generated functional mini- and micro-dystrophins that could be efficiently packaged into 
AAV virions and demonstrated efficient transfer in mice. The development of AAV vectors 
for gene therapy of lung diseases, focusing on cystic fibrosis also seems to be very promising. 
Flotte et al. (1993) were among the first to demonstrate successful and stable in vivo gene 
transfer to the airway epithelium with an AAV vector expressing the cystic fibrosis 
transmembrane conductance regulator cDNA. Actually, most clinical trials involving AAV 
vectors deal with the treatment of cystic fibrosis (Griesenbach et al. 2002). Finally, several 
studies demonstrated the potential of AAV in cancer gene therapy. Currently, various 
approaches are being used for the therapy of malignancies, including the delivery of a 
combination of genes and prodrugs that exhibit cytotoxicity on tumor cells, modulation of 
oncogenes and tumor suppressor genes, inhibition of tumor vascularization and enhancement 
of the host immunity against tumor cells. Interestingly, AAV itself seems to have antitumor 
properties which were initially attributed to the down-regulation of proto-oncogene promoters 
by the large Rep proteins and induction of cell cycle arrest (Hermonat 1994; Saudan et al. 
2000). The nature of the single-stranded AAV genome also seems to be tumor protective by 
inducing apoptosis in cells lacking active p53, an important tumor suppressor found to be 
switched off in many human cancers (Raj et al. 2001). Moreover, rAAV vectors have proven 
their potential in various cancer gene therapy approaches, e.g. cancer immunotherapy using 
cytokines and co-stimulatory molecules to induce an antitumor T-cell response (Anderson et 
al. 1997; Chiorini et al. 1995; Wendtner et al. 2002), and transfer of antiangiogenic molecules 
to inhibit growth of tumor neovasculature (Nguyen et al. 1998).  
Overall, adeno-associated viruses are very promising gene transfer vehicles for 
treatment of multiple diseases. The increasing interest in AAV as vector system and the rising 
amount of gene therapy trials which are currently under investigation argue for its potential as 
human gene therapy vector. Hurdles, however, still exist and have to be overcome, including 
specific and selective transduction of the target tissue, potential immune response to the 
vector and/or transgene, and loss of specific integration of recombinant AAV vectors. Some 
of these limitations have been addressed in the studies presented here: the requirements for 
targeted integration of recombinant vectors were investigated and an AAV vector construct 
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with the potential for site-specific integration was developed. Antigenic determinants of the 
AAV capsid were characterized in binding studies with human serum samples. Moreover, an 
AAV capsid mutant with the ability to escape neutralization by human antisera was identified. 
These results represent further steps towards an improved generation of AAV vectors for 
human gene therapy. 
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Abstract 
Background. Recombinant adeno-associated virus (rAAV) has many advantages for gene 
therapeutic applications in comparison to other vector systems. One of the most promising 
features is the ability of wild-type (wt) AAV to integrate site-specifically into human 
chromosome 19. However, this feature is lost in rAAV vectors due to the removal of the Rep 
coding sequences.  
Methods. HeLa cells were transfected with a Rep expression plasmid, infected by rAAV and 
grown with or without selection pressure. Single cell clones were generated and genomic 
DNA was analyzed for site-specific integration by Southern blotting analysis and 
fluorescence in situ hybridization (FISH).  
Results. Transfection of HeLa cells with a Rep expression plasmid followed by the 
transduction with a rAAV vector resulted in site-specific integration of the transgene at 
AAVS1 on human chromosome 19 in 7 of 10 cell clones analyzed. In marked contrast, 
transduction of cells with rAAV alone did not result in any site-specific integration of the 
transgene.  
Conclusions. The high frequency with which the site-specific integration took place in the 
presence of Rep protein is comparable to the results observed with wtAAV. These results 
offer opportunities for the development of specifically integrating rAAV vectors. 
 
Introduction 
The development of safe, stable and efficient gene transfer vehicles is one of the most critical 
steps for the success of gene therapy. One of the most promising vectors is derived from the 
adeno-associated virus type 2 (AAV), a member of the parvovirus family. AAV has many 
advantages in comparison to other vector systems, e.g. its ability to transduce both dividing 
and non-dividing cells, its low immunogenicity and the apparent lack of pathogenicity. One of 
the most encouraging features of AAV is its ability to integrate site-specifically into the distal 
portion of the q arm of human chromosome 19. For this integration step only two viral 
elements are necessary, namely, the Rep proteins and the inverted terminal repeats (ITR) 
(Giraud et al. 1994; Kotin et al. 1992; Kotin et al. 1990; Lamartina et al. 2000; Samulski et al. 
1987). 
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The viral genome is a single stranded DNA of 4.7 kb, containing the palindromic ITR 
sequences at both ends. These ITRs are not only required for the integration process, but 
serve also as origin of replication, are required for rescue of the provirus after integration and 
for encapsidation of the viral genome. In between these ITR structures two open reading 
frames, rep and cap, are found. rep encodes four overlapping, multifunctional proteins 
(Rep78, Rep68, Rep52 and Rep40) controlled by two different promoters (Balague et al. 
1997). The transcription of the large Rep proteins (Rep78 and its splice variant Rep68) is 
controlled by the p5 promoter. They are necessary for viral DNA replication, transcriptional 
control and site-specific integration. Rep52 and its splice variant Rep40 are known as small 
Rep proteins. They are transcribed from the p19 promoter and play an essential role in the 
accumulation of single-stranded progeny genomes used for packaging. The 3’ ORF cap 
accommodates the three capsid proteins VP1, VP2 and VP3. They are transcribed from the 
p40 promoter and form the viral capsid, which is an icosahedrons of 20 to 25 nm in diameter. 
After entry into the cell AAV depends on a helper virus, such as adenovirus or 
herpesvirus, for efficient replication and reproduction. In the absence of the helper virus, 
AAV latently infects cells by integrating into the host genome. In most cases (70-80%) this 
integration was found at AAVS1 (Kotin et al. 1990; Shelling & Smith 1994), which is located 
in the human chromosome 19 within 19q13.4 (Dutheil et al. 2000). Subsequent super 
infection of AAV latently infected cells with the helper virus results in the rescue of the 
provirus, in the replication of the AAV genome and the production of new viral particles 
(Kotin 1994). 
The ability to integrate site-specifically into a distinct region of the human genome, 
resulting in stable and efficient gene expression without adverse effects on the host cell, 
would be an ideal situation for the development of viral vectors designed for long-term gene 
expression in human cells. However, commonly used rAAV vectors do not target to AAVS1, 
because they do not express the rep genes (Flotte & Carter 1995; Linden et al. 1996a). As it is 
known that supplying the Rep protein in trans can help to overcome this limitation (Surosky 
et al. 1997), we wanted to define the conditions and develop appropriate methods for the 
analysis of site-specific transgene integration following transduction with rAAV vectors in 
vitro.  
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Materials and Methods 
Plasmids. The pRC plasmid was constructed as previously described (Girod et al. 1999). Briefly, the 4.5 kb Xba 
I-fragment of psub201(+)(Samulski et al. 1987), containing the rep and cap ORFs of AAV was subcloned into 
the Pst I and BamH I sites of pSV40oriAAV (Chiorini et al. 1995).The pGFP plasmid is an AAV-based vector 
plasmid in which the AAV ITR sequences are flanking the hygromycin selectable marker gene controlled by the 
thymidine kinase promoter and the Aequorea victoria Green Fluorescence Protein (GFP) gene regulated by the 
cytomegalovirus promoter. pGFP was generated by inserting the Asp718-Not I fragment of pEGFP-N1 
(Clontech) into the Asp718-Not I sites of psub/CEP4(Sal invers). psub/Cep4(Sal invers) is a derivative of 
psub201(+) (Samulski et al. 1987), which was digested with Xba I, blunt ended and ligated to blunt ended 3923 
bp Sal I-Nru I-Fragment of pCEP4(Sal inverse). pCEP4(Sal inverse) differs from pCEP4 (Invitrogen) by 
inversion of the Sal I (8)-Sal I (1316)-fragment. 
Cell culture. The human cervix epitheloid carcinoma cell line HeLa (ATCC CCL 2; American Type Culture 
Collection, Rockville, Maryland) was maintained as monolayer culture at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM), supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 
mg/ml streptomycin and 2 mM L-glutamine. 
Production of rAAV vector particles. The rAAV vectors were generated as described (Girod et al. 1999). 
Briefly, HeLa cells were seeded at 10% confluency in 15 cm dishes and transfected with 17.5 µg of vector 
plasmid pGFP and 17.5 µg of helper plasmid pRC by adding a 1:1 mixture of 2x BBS (50 mM BES (N,N-bis(2-
hydroxyethyl)-2-aminoethanesulfonic acid), pH 6.95, containing 280 mM NaCl, 0.75 mM Na2HPO4 and 0.75 
mM NaH2PO4) and 260 mM CaCl2 and subsequently incubated 18-22 hours at 35°C and 3% CO2. At 48 hours 
after transfection, cells were incubated with adenovirus type 5 (MOI 5) for 1 hour in 10 ml of serum-free 
medium and then supplemented with 10 ml of medium containing 20% FCS. At 72 hrs after adenovirus type 5 
infection the rAAV vector particles were purified and concentrated by two cycles of ultracentrifugation on CsCl 
gradients (ρ  = 1.4 g/ml) as described (Chiorini et al. 1995). After dialysis against 1x PBS the concentration of 
DNA containing viral particles and of transducing rAAV viral particles was determined by standard procedures 
(Girod et al. 1999).  
Immunofluorescence assay. HeLa cells were seeded at 10% confluency on slides in 15 cm dishes and 
transfected with 35 µg of helper plasmid pRC as described for the rAAV vector production. 12, 24, 36 and 45 
hours after transfection Rep protein synthesis was analyzed in an immunofluorescence assay (Wistuba et al. 
1997). As a control, HeLa cells were infected with wtAAV (MOI 3) in an adenovirus type 5 (MOI 5) containing 
medium, incubated for 16 hours and then analyzed for Rep expression. 
Cotransfection. 1.5x105 HeLa cells were seeded in 6-well-plates and transfected with the 2.5 g pRC as 
described for rAAV vector production. After 24 hours, the cells were infected with rAAV-GFP/Hygro at a MOI 
4. One part of the cotransfected cells was grown in the presence of hygromycin (350 µg/ml), whereas the other 
part was cultivated without selection pressure. As a control, HeLa cells were only infected with rAAV-
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GFP/Hygro and not transfected with pRC, and treated in the same manner. Single cell clones were generated 
from the GFP expressing cells by limiting dilution and cultivated for Southern blot and FISH analysis. 
Southern blot analysis. Genomic DNA was isolated by standard methods. Briefly, cells were harvested, lysed 
with 1% Sarcosyl in 75 mM Tris-HCl, pH 8.0, 25 mM EDTA and incubated with Proteinase K (100 µg/ml) at 
50°C overnight. After phenol/chloroform extraction RNA was removed by incubation with RNase (100 µg/ml). 
The genomic DNA solution was dialyzed against TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA) and 
digested with EcoR I. EcoR I cuts twice in rAAV-GFP/Hygro (Fig. 1a) and at position 2 in AAVS1 (S51329). 
Another EcoR I site is found approximately 8.2 kb upstream, outside the AAVS1. The DNA was then separated 
by agarose gel electrophoresis (0.8%) and blotted to a nylon membrane. The membrane was hybridized with a 
random-primed transgene probe by standard methods, an autoradiogram was taken, the membrane was stripped 
and then hybridized with a random-primed AAVS1-specific probe and exposed again. The transgene probe 
encompasses the GFP and the hygromycin resistance sequences of pGFP (Fig. 1a) and was generated by a Pst I 
digest. The AAVS1-specific probe includes position 1439-2527 of AAVS1 cloned into pRIA-N3 and was also 
generated by Pst I digest. pRIA-N3 was kindly provided by R. Kotin. 
Chromosomal fluorescence in situ hybridization (FISH). After fixation in methanol:acetic acid 3:1, the cells 
were air dried on glass slides and frozen at –20°C for at least one day. The pGFP was digested with Spe I and 
then labeled with biotin-11-dUTP using a nick translation labeling kit (Roche Diagnostics, Mannheim, 
Germany). 10 ng of labeled and precipitated DNA was dissolved in 10 µl hybridization solution consisting of 
50% formamide, 10% dextran sulfate, 1x SSC, 5 µg sonicated salmon sperm DNA, and then denatured at 95°C 
for 5 min. Slides with metaphase spreads were first dehydrated by passing through a graded ethanol series. Then 
they were denatured in 70% formamide/2x SSC at 72°C for 2 min on a heating plate and subsequently passed 
through a graded ethanol series. Hybridization was performed in 10 µl hybridization solution/4cm2 at 37°C 
overnight under a cover slip sealed with rubber cement. Post-hybridization washes were performed in 0.4x SSC 
at 72°C for 2 min and 2x SSC at room temperature for 2 min, followed by 30 min incubation with 5% nonfat dry 
milk/4x SSC at room temperature. Immunochemical detection of the biotin labeled probe was carried out with 
fluorescein isothiocyanate (FITC)-conjugated avidin (Vector, Burlingame, CA) as described (Lichter et al. 
1988). The signal was amplified by using biotinylated goat anti-avidin immunoglobulins (Vector). The slides 
were counterstained with 4,6-diamino-2-phenylindol (DAPI) (2mg/mL) and mounted in anti-fade solution (90% 
glycerol, 10% PBS, 1 mg/ml phenylenediamine). After microscopy the cover slips and anti-fade solution was 
removed by incubation in 2x SSC for at least 2 hrs. The whole chromosome 19 painting probe labeled with 
Spectrum Orange was purchased from Vysis (Bergisch Gladbach, Germany) and hybridization was carried out 
according to the manufacturers instructions. Metaphases were analyzed using a Zeiss Axioskop epifluorescence 
microscope equipped with filter combinations according to Pinkel (AHF Analysentechnik, Tübingen, Germany) 
and a cooled charge-coupled device camera. FITC, Spectrum Orange, and DAPI fluorescence were recorded 
separately as gray-scale images by only changing the excitation wave length while the beam splitter and 
emission filter remained in position. The images were then pseudocoloured and were merged using a digital 
image analysis software program (ISIS, Metasystem, Altlussheim). 
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Results  
Construction of the plasmids and functional testing 
A unique characteristic of wild-type (wt) AAV is its ability to integrate site-specifically into 
the human chromosome 19 (AAVS1). Although rAAV can integrate into the genome, the 
specificity for AAVS1 is lost due to the absence of the large Rep proteins. Therefore, we have 
initiated studies to determine if Rep proteins expressed in trans from a suitable co-transfected 
plasmid could promote site-specific integration of rAAV.  
For these studies two plasmids, pGFP and pRC, were generated. pGFP was cloned as 
described in Material and Methods. It was used as the vector plasmid in the packaging 
process of rAAV-GFP/Hygro. pGFP encodes the transgenes for Green Fluorescence Protein 
(GFP) and hygromycin resistance, controlled by the cytomegalovirus and the thymidine 
kinase promoter, respectively (Fig. 1a). GFP was chosen as transgene, because its expression 
facilitates the determination of transfection efficiency and stability of gene expression. To 
study the influence of antibiotic selection pressure on the site-specific integration process, the 
hygromycin resistance gene was included in the vector plasmid. The two genes were flanked 
by the viral inverted terminal repeats (ITR), the sole cis elements required for packaging 
AAV.  
The plasmid pRC encodes the Rep and Cap proteins of wtAAV controlled by their 
natural promoters (Fig. 1b). This plasmid was employed as helper plasmid for packaging 
rAAV (Material and Method) and, furthermore, to express Rep in trans in the genomic 
targeting approach described in this article. Providing Rep in trans by a Rep expressing 
plasmid lacking the ITR of AAV and other integration promoting signals was expected to 
have the following advantages: (i) integration of rAAV vectors in a site-specific manner, 
(ii) preservation of the full transgene coding capacity of the rAAV vectors, and (iii) transient 
expression of the potentially cytotoxic Rep proteins. 
In the first experiments we intended to determine whether the Rep proteins controlled 
by their natural promoter were expressed in HeLa cells in the absence of helper virus co-
infection. For this purpose HeLa cells were transfected with the plasmid pRC by calcium 
phosphate precipitation and the transfection was stopped by fixation of the cells at different 
time points (12, 24, 36 and 45 hours after transfection). Immunostaining techniques were used 
to determine the expression of Rep proteins. As a positive control HeLa cells were 
cotransfected with wtAAV and adenovirus type 5, cultivated for 16 hours, and analyzed for 
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Rep expression. In this experiment, Rep expression could easily be detected at 24 hours post 
transfection (Fig. 2a). Expression increased and reached a plateau at 36 hours post 
transfection (Fig. 2b), and declined thereafter (Fig. 2c). Although after co-infection of 
wtAAV and adenovirus expression of Rep was visible at an earlier time point (Fig. 2d), these 
results clearly demonstrated that Rep was synthesized in significant quantities from the Rep 
expressing plasmid pRC in the absence of adenovirus type 5. 
 
Production of stable GFP expression cell lines 
Since Rep was expressed after transfection of pRC in the absence of helper virus in HeLa 
cells (Fig. 2), we next examined whether this Rep expression was able to mediate the site-
specific integration of rAAV. Moreover, we wanted to determine whether antibiotic selection 
pressure negatively influenced site-specific integration. Together, 25 single cell clones 
generated under four different experimental conditions (Table 1) were investigated. Groups 1 
and 2 were obtained by transfecting HeLa cells with pRC 24 hours before rAAV-GFP/Hygro 
infection. Half of these co-transfected cells were then grown in the presence of hygromycin 
(350 µg/ml) starting 48 hours after infection (group 2), while the other half was cultivated 
without selection pressure (group 1). 14 days later, single cell clones were obtained by 
limiting dilution and expansion of the GFP expressing cell clones, resulting in 4 clones in 
group 1, and 6 clones in group 2. As controls (groups 3 and 4), single cell clones were 
obtained by infecting HeLa cells with rAAV-GFP/Hygro followed by cultivation in the 
absence (group 3) or presence (group 4) of hygromycin. By this approach, 9 cell clones were 
obtained in group 3, and 6 clones in group 4, respectively. All 25 single cell clones stably 
expressed GFP for more than eight months in culture, although the initial high levels of GFP 
expression started to decrease slowly after week 4.  
To estimate of the overall integration frequency of rAAV-GFP/Hygro, the polyclonal 
cell population of group 1 and 3, which were kept without selection pressure after infection, 
was monitored for GFP expression for one month. Two days after infection, both cell 
populations showed a high number of GFP positive cells, indicating a transduction efficiency 
of more than 70%. After one month, 45 % of the cells infected with rAAV-GFP/Hygro after 
pRC transfection remained positive for GFP fluorescence. In marked contrast, less than 2% of 
the cells transduced with rAAV-GFP/Hygro but not transfected with pRC showed GFP 
expression. This indicated that transfection of a Rep expressing plasmid alone was able to 
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significantly increase the overall integration frequency in agreement with previous studies 
(Balague et al. 1997).  
 
 
Table 1. AAVS1 specific integration after rAAV-GFP/Hygro  
infection and co-transfection with pRC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Four experimental groups with a total of 25 single cell clones were established. In groups 1 and 2 Rep 
was provided by transfection of pRC 24 hours before rAAV-GFP/Hygro infection. The cells were 
subsequently grown in the absence (group 1: clones B6, D6, F3 and H6) or presence (group 2: clones 
A3, B12, C2, C10, D4 and F4) of hygromycin (350 µg/ml). The clones belonging to groups 3 and 4 
were generated by infection with rAAV-GFP/Hygro without prior transfection of pRC and then 
growing in the absence (group 3: clones 1B11, 1D11, 2D10, 4A7, 4G1, 5B10, 5F2, 6B2 and 6B11) or 
presence (group 4: clones B9, C4, C11.5, C11.7, G5 and H11) of hygromycin (350 µg/ml). 
(n.d.: not determined; 1of the clones analyzed by this method) 
 
 
Experimental condition Group 1 Group 2 Group 3 Group 4
Transfection with pRC + + - - 
Transduction with rAAV-GFP/Hygro + + + + 
Selection with hygromycin - + - + 
Results      
GFP positive clones 4/4 6/6 9/9 6/6 
AAVS1 integration (Southern blot 
with EcoR I) 
1/4 6/6 0/9 0/6 
Transgene signal on chromosome 19 
(FISH)1  
1/1 4/4 n.d. 0/1 
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Site-specific integration of the transgene occurs only in the co-transfected cells 
To test whether site-specific integration of rAAV-GFP/Hygro in AAVS1 occurred in any of 
the 25 GFP expressing single cell clones, Southern blot analysis of EcoR I digested genomic 
DNA was performed. This restriction enzyme cuts twice within rAAV-GFP/Hygro (Fig. 1a) 
and at position 2 of the GenBank deposited sequence of AAVS1 (S51329) (Kotin et al. 1992).  
A site-specific integration event was expected to result in at least one up shifted band with 
respect to the normal AAVS1 site present in the parental HeLa cell line, and the transgene 
should also be detectable at this site. Therefore, the Southern blot membrane was first 
hybridized with a transgene specific probe and then, after removal of the first probe, with an 
AAVS1 specific probe. The hybridization pattern9 obtained with the two different probes was 
then compared.  
Figure 3 shows the Southern blot results of the 10 independent clones generated by 
cotransfection of the Rep expression plasmid pRC and rAAV-GFP/Hygro. Six of these clones 
(A3, B12, C2, C10, D4, F4) were grown in the presence of hygromycin (group 2), whereas 
the remaining were cultivated in the absence of hygromycin (group 1). In all clones (Fig. 3b) 
additional higher migrating AAVS1 specific fragments were detectable in comparison to the 
uninfected HeLa cell control (Fig. 3b), one criteria pointing towards a site-specific integration 
event. Moreover, the up shifted band co-hybridized with the transgene specific probe in 7 of 
10 clones (H6, A3, B12, C2, C10, D4, F4) (compare Fig. 3a with 3b). This demonstrated that 
providing Rep in trans by cotransfection allowed to target the genomic integration of rAAV 
vectors to AAVS1. Integration of AAV as head-to-tail concatamers have been described 
previously (Yang et al. 1997). Such an integration would result in an additional transgene 
specific signal of 4.5 kb which could not be observed (Fig. 3). Other concatameric forms such 
as head-to-head and tail-to-tail integration can also be excluded on the basis of the banding 
pattern. 
Similarly, clones obtained by rAAV-GFP/Hygro infection without pRC 
cotransfection, followed by culture in the absence (group 3) or presence (group 4) of 
hygromycin, were analyzed by EcoR I Southern blot. Figure 4 shows a representative blot of 
10 out of a total of 15 clones obtained. None of the clones, including those not shown, 
displayed a banding pattern in which the transgene signal co-migrated with the AAVS1 
specific signal (compare Fig. 4a with 4b). Furthermore, all clones showed the presence of a 
single AAVS1 specific signal (Fig. 4b). Both findings suggest that no site-specific transgene 
integration occurred in the absence of pRC transfection. 
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Taken together, the Southern blot analysis revealed that no site-specific integration 
event occurred in the absence of rep gene expression (0/15). In contrast, site-specific 
integration of rAAV-GFP/Hygro at AAVS1 was seen in the majority of the clones obtained 
by cotransfection of the rep gene (7/10). 
 
FISH analysis of the HeLa cell clones confirms integration at chromosome 19 in 
the presence of Rep 
To confirm the Southern blot results, fluorescence in situ hybridization analysis (FISH) of the 
five HeLa cell clones A3, B12, C10, D4 and H6 was performed. As controls, uninfected HeLa 
cells and clone G5 were analyzed. For this FISH analysis two probes were used, the 7.9 kb 
pGFP and a probe for chromosome 19 (see Material and Methods).  
Before starting FISH analysis, the parental HeLa cell line was characterized by 
conventional chromosome banding analysis (Fig. 5a). In agreement with previous literature, 
numerous chromosomal aberrations were detected in this cell line. Regarding chromosome 
19, one normal chromosome and two chromosomes with a translocation t(13;19) were 
detected (Fig. 5a), as described previously by Macville and colleagues (1999). 
Thereafter, a FISH analysis of the metaphase chromosomes of the above cell clones 
was performed. The red dye shown in Figure 5b-h indicates chromosome 19, whereas the 
yellow spots show the hybridized transgene probe. The uninfected HeLa cell clone (Fig. 5b) 
hybridized only with the chromosome 19 specific probe, revealing one signal for each 
chromosome 19. Figure 5h shows the clone G5 (group 4). This clone was generated through 
infection with rAAV-GFP/Hygro in the absence of rep gene expression and did not show any 
evidence for site-specific transgene integration in Southern blots. In FISH analysis, the red 
signals specific for chromosome 19 were visible. In addition, rAAV-GFP/Hygro specific 
signals were detectable on one of the D group chromosomes (chromosome 13, 14 or 15), 
confirming that rAAV had integrated at a site different from AAVS1. Thus, the FISH analysis 
supported the Southern blot results for the clone G5. In marked contrast, clones A3, B12, 
C10, D4 and H6 resulting from cotransfection of pRC and rAAV-GFP/Hygro (groups 1 and 
2) showed a site-specific integration by FISH analysis in each clone, as demonstrated by the 
co-localization of the rAAV specific probe with chromosome 19 (Fig. 5c-g). Moreover, this 
co-localization was consistently visible on the q arm. This result strongly suggested that a 
site-specific integration of the GFP gene at AAVS1 had occurred. 
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In summary, the FISH analysis confirmed the Southern blot results for every clone 
analyzed. The results suggest that providing Rep in trans by cotransfection of a plasmid 
vector is sufficient to achieve site-specific integration of an ITR flanked transgene carried by 
an AAV vector. 
 
Discussion 
Avoiding insertional mutations by random integration is a major concern when gene therapy 
needs long-term gene expression in normal tissue. Up to now AAV is the only known virus 
capable of site-specific integration into the human chromosome. For this specific integration 
process, the viral encoded Rep proteins and the ITR structures flanking the vector genome are 
required. However, in the commonly used rAAV vectors only the ITR structures are retained, 
which results in the loss of integration specificity. Not only safety concerns (in particular with 
regard to homologous recombination during rAAV packaging), but also the limited packaging 
capacity (Dong et al. 1996), reduce the possibility of constructing rAAV vectors which retain 
the rep gene in cis to mediate site-specific integration. 
One potential approach to overcome this problem was described by Balagué et al. 
(1997). They could show that transfecting a plasmid containing both an ITR flanked 
transgene and a Rep expression cassette outside the ITRs into 293 cells resulted in the site-
specific integration of the transgene into AAVS1. However, Tsunoda et al. (2000) and 
Surosky et al. (1997) observed that the entire plasmid backbone, not only the ITR flanked 
transgene, integrated into the AAVS1 at a high frequency, when the rep gene was provided on 
the same or on a co-transfected plasmid.  
For this reason we chose a different approach. The Rep expression plasmid pRC was 
transfected independently of the transgene into HeLa cells. This approach allowed to express 
Rep in significant quantities in the absence of any helper virus such as adenovirus type 5. 
Subsequent infection of cells with a rAAV vector caused site-specific integration of the GFP 
transgene in 70% of the clones. Integration occurred regardless of whether the cells were 
grown under selection pressure with hygromycin or not. In marked contrast, no transgene 
integration at AAVS1 was obtained when cells were infected by rAAV-GFP/Hygro without 
prior pRC transfection (Fig. 3 and 5). 
In contrast to Balagué et al. (1997) who assumed that selection pressure interfered 
with the site-specific integration event, we observed integration at AAVS1 also in the 
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presence of hygromycin selection at high frequency (6/6). Moreover, the GFP expression 
level was sustained at much higher levels in clones grown with selection than in those grown 
without selection. Since Balagué et al. (1997) did not provide a detailed description of their 
selection procedure, the explanation for this difference is not obvious. One reason might be 
the time point at which the selection pressure was started (in our experiments 48 hours after 
rAAV infection). 
HeLa cells contain only one normal chromosome 19 and two t(13;19) translocations 
(Fig. 5). The translocation event occurs in both t(13;19) cases at the p arm of chromosome 19, 
i.e. far from AAVS1 (19q13.4) (Macville et al. 1999). A negative influence of the 
chromosomal translocation on the integration process could not be excluded at the beginning 
of our studies. However, our FISH results suggest that this is not the case. In two clones, H6 
and C10, rAAV integrated into one of these translocated chromosomes. Integration into the 
normal chromosome 19 took place in the remaining three clones analyzed by FISH (A3, B12 
and D4). In addition to this, none of the clones in which rAAV had integrated specifically at 
AAVS1, showed integration into an additional chromosome. This argues for a relatively high 
specificity of Rep mediated integration. The ITRs are integration promoting signals. This was 
demonstrated by Balagué and colleagues (1997) who compared the integration frequency of 
ITR containing plasmids with plasmids lacking the ITR sequence.  
For directing the ITR containing sequence to the AAVS1 site, at least one of the large 
Rep proteins is necessary. One model for site-specific integration (Brister & Muzyczka 2000; 
Meneses et al. 2000) proposes that Rep78 and/or Rep68 bind as a multimeric complex both to 
the Rep binding site (RBS) on chromosome 19 and to the viral DNA. Rep then nicks at the 
chromosomal terminal resolution site (trs), possibly aided by cellular proteins (Costello et al. 
1997; Dyall et al. 1999). Subsequently, Rep initiates a strand displacement DNA synthesis, 
during which DNA template switches occur linking viral with cellular DNA. Also other 
models for targeted integration are possible, e.g. integration could be mediated by ligase 
activity of the large Rep proteins (Smith & Kotin 2000). Meneses and colleagues (2000) 
showed that three parameters are necessary for the integration process: 1) RBS, 2) trs and 3) a 
spacer sequence, containing either a GCTC motif or two CTC triplets embedded in a 
pyrimidine-rich sequence. The specific combination of these three parameters can only be 
found once in the human genome, in AAVS1, which could explain the specificity of the 
integration process. 
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The clones C2, D4 and F4 were obtained by cotransfection of pRC and rAAV-
GFP/Hygro (group 2) and showed site-specific integration by Southern blot analysis. In these 
clones an additional up shifted AAVS1-specific band was detected (Fig. 3b), which showed 
no co-hybridization with the transgene probe. The FISH analysis of D4 (Fig. 5f) confirmed 
the presence of an additional chromosome 19 specific signal. These results demonstrate Rep 
dependent rearrangements of AAVS1, since none of the control clones obtained by rAAV 
alone (groups 3 and 4) showed such a pattern (Fig. 4). However, such rearrangements did not 
occur consistently in all clones (Fig. 3b). Further studies on the function of Rep and the 
integration process will elucidate this event and hopefully the design of strategies to avoid 
these rearrangements. 
The three clones B6, D6 and F3 were negative for the occurrence of site-specific 
integration in the EcoR I Southern blot analysis, although they were obtained by 
cotransfection of pRC and rAAV-GFP/Hygro (group 1) and although they all showed 
additional AAVS1-specific bands pointing towards Rep activity. One explanation for this 
might be that the level of Rep expression was lower than necessary (Young et al. 2000) or 
occurred too late to mediate the specific integration. Another explanation could be that these 
clones integrated site-specifically but the orientation of the integrated transgene was inverted. 
In this case it would not be possible to detect site specific integration using EcoR I as 
restriction enzyme (Fig. 1). To test this point, we performed a Southern blot using Bcl I, 
which cuts neither in the rAAV used nor in AAVS1. This resulted in an up shifted band in 
comparison to the parental cell line (data not shown). Moreover, this band co-hybridized with 
the transgene specific probe (data not shown). Both observations argue for the occurrence of 
site-specific integration of the transgene in these clones, detection of which failed when using 
EcoR I to digest the genomic DNA.  
Another characteristic of AAV is the ability of the integrated viral genome to rescue 
from the latent state and reenter the lytic life cycle, when helper functions are provided. This 
was observed with wtAAV and rAAV preferentially when the viral genome had integrated as 
concatamer and/or when at least one ITR was still intact after integration (McLaughlin et al. 
1988; Rutledge & Russell 1997). We therefore tested the specifically integrated clones for 
rescue and replication of the proviral genome after transduction with pRC and adenovirus. In 
our setting all clones were rescue deficient, although in control transfections virus production 
could be observed (data not shown). One explanation for the rescue deficiency could be that 
AAV had integrated as a monomer and that deletions and rearrangements in the ITRs had 
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occurred during the integration process. This is in agreement with our Southern blot results in 
which the banding pattern also points towards monomeric integration. Further studies are now 
ongoing to determine the molecular structure of the integration junctions.  
In conclusion, our results show that providing Rep in trans by the described 
cotransfection approach is a very efficient method to achieve site-specific integration of the 
commonly used rAAV vectors in vitro. In particular for ex vivo gene therapy of diseases of 
the hematopoietic system, e.g. by gene transfer into CD34+ stem cells, it would be beneficial 
to use the described system to achieve efficient and specific integration of  transgenes. On this 
promising basis we are now developing methods suitable for genomic in vivo targeting of 
rAAV vectors. 
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Figure 1. Schematic representation of the plasmid constructs used. (a) The plasmid pGFP encodes, flanked 
by the AAV ITR sequences, the genes for the Aequorea victoria Green Fluorescence Protein (GFP) and the 
hygromycin resistance gene controlled by the cytomegalovirus promoter and the thymidine kinase promoter, 
respectively. The important restriction sites and the size of the fragments obtained after digestion of the AAV 
genome with EcoR I are marked. The probe used to detect the transgene encompassed the region indicated. b) 
The plasmid pRC contains the rep and cap genes of wtAAV, controlled by its natural promoters p5, p19 and 
p40. 
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Figure 2. Rep protein synthesis in the absence of adenoviral gene products. HeLa cells were transfected 
with pRC by calcium phosphate precipitation. The transfection was stopped at different time points by fixation 
with methanol and acetone. Cells were then analyzed for Rep expression by immunostaining. Fig. 2a-c shows 
the Rep expression detected after 24, 36 and 45 hours. Fig. 2d shows the amount of Rep expression visible 16 
hours after wtAAV and adenovirus co-infection of HeLa cells with an MOI 3 and 5, respectively. 
 
a )
24h after pRC transduction
b )
  36h after pRC transduction
d )
16h after wtAAV infection
c )
45h after pRC transduction
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Figure 3. EcoR I Southern blot of the cell clones generated by pRC and rAAV-GFP/Hygro cotransfection. 
The genomic DNA was isolated from different cells. Clones B6, D6, F3 and H6 were grown without selection 
pressure (group 1), while clones A3, B12, C2, C10, D4 and F4 were grown in the presence of hygromycin 
(350 µg/ml) (group 2). The genomic DNA was digested with the restriction enzyme EcoR I (for details see 
Material and Methods). After electrophoresis Southern hybridization with the transgene probe was 
performed (a). After exposure the membrane was stripped and hybridized with an AAVS1 probe (b). Arrows 
indicate bands which hybridized to the transgene probe as well as to the AAVS1 probe. The position of the 
molecular weight DNA marker is indicated on the left. 
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Figure 4. EcoR I Southern blot of cell clones generated by rAAV-GFP/Hygro infection without pRC 
cotransfection. The genomic DNA was isolated from different cell clones grown in the absence (group 3: 5B10, 
5F2, 6B2, 6B11) or presence (group 4: B9, C4, C11.5, C11.7, G5, H11) of hygromycin (350 µg/ml). The 
genomic DNA was digested with the restriction enzyme EcoR I and treated as described in Fig. 3 and in 
Materials and Methods. The position of the molecular weight DNA marker is indicated on the left. 
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Figure 5. Chromosome banding analysis of the HeLa cell line used and FISH analysis. (a) Chromosome 
banding analysis of the HeLa cell line used. Numbers indicate the chromosome number. The colors help to 
associate the translocations with the corresponding ”mother” chromosome. Three chromosome 19s could be 
detected (one normal and two t(13;19) translocations). (b-h) FISH analysis of the metaphase chromosomes of 
the HeLa cell line and of the cell clones A3, B12, C10, D4, H6 and G5. The red dye indicates the 
chromosome 19 specific signal, the yellow spots are the hybridization signals of the transgene probe. 
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Abstract 
Adeno-associated virus type 2 (AAV) has many features that makes it an attractive vector for 
human gene therapy. A unique advantage of wild-type AAV is the ability to specifically 
integrate into the human genome at a distinct locus within chromosome 19 (AAVS1), 
especially with regard to stable transgene expression and avoiding the risk of insertional 
mutagenesis by random integration. However, recombinant AAV vectors have lost this ability 
due to the deletion of the viral rep gene. Previously we could show that targeted integration 
can be restored by providing rep-DNA in trans (Huttner et al. 2003). To design specifically 
integrating recombinant AAV vectors we decided to couple rep as polylysine/DNA complex 
via a biotin-streptavidin bridge directly to the AAV capsid.. In this study we demonstrated 
that a Rep encoding plasmid can be efficiently packaged by polylysine (PLL) into small 
compact particles. These complexes could be coupled to biotinylated AAV particles via a 
biotin-streptavidin bridge. Moreover, we could show that the biotin labeling of AAV and the 
linkage of streptavidin did not interfere with the viral infection process. Interestingly, AAV-
PLL/DNA complexes were able to infect HeLa cells and could be observed in the cytoplasm 
by single-molecule microscopy in real-time, while PLL/DNA complexes alone did not enter 
cells. These findings are an important step towards specifically integrating AAV vectors for 
the use in human gene therapy. 
 
Introduction 
Adeno-associated virus type 2 (AAV) is a small, replication defective, DNA virus that has 
promising features as a vector for human gene therapy. Both wild-type and recombinant AAV 
display a wide target cell tropism, transduce terminally differentiated and non-dividing cells, 
and show low immunogenicity and no pathogenicity (Monahan & Samulski 2000). One of the 
most promising features of AAV is its ability to integrate site-specifically into the human 
chromosome (Berns & Giraud 1996). 
AAV is a member of the Parvoviridae family with a small icosahedral capsid 
harboring a single-stranded DNA genome of approximately 4.7 kb. The genome consists of 
two open reading frames (ORF), which comprise the rep and cap genes, and is flanked by the 
inverted terminal repeats (ITR). The ITRs serve as the origins of replication for viral DNA 
synthesis and are required for packaging and targeted integration. The 5’ ORF encodes four 
non-structural proteins, Rep78, Rep68, Rep52, and Rep40. The large Rep proteins (Rep78 and 
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Rep68) are required for viral replication, transcriptional control and site-specific integration. 
The small Rep proteins (Rep52 and Rep40) play an essential role in the accumulation of viral 
DNA into preformed capsids. The three capsid proteins VP1, VP2, and VP3 are encoded in 
the 3’ ORF. They form the icosahedral capsid, which has a diameter of 25 nm. 
To persist in nature AAV utilizes a biphasic life cycle. In the presence of helper virus, 
adenovirus (Ad) or herpesvirus, wild-type AAV (wtAAV) undergoes a productive infection. 
Lacking a helper virus, wtAAV latently infects by integrating into the host genome 
preferentially (> 70%) into human chromosome 19 within 19q13.4 (AAVS1) (Berns & 
Giraud 1996). The ability of this virus to integrate site-specifically has made it an attractive 
candidate vector for human gene therapy. For targeted integration the non-structural proteins 
Rep78 and/or Rep68 are required; the ITRs flanking the vector genome are the essential cis 
components (McLaughlin et al. 1988; Samulski et al. 1989; Xiao et al. 1997b). In the absence 
of Rep proteins, the virus can still integrate through the ITR sequences but randomly into the 
host genome (Kearns et al. 1996; Walsh et al. 1992; Xiao et al. 1997b). However, commonly 
used recombinant AAV vectors (rAAV) lack the viral rep gene, only the ITRs are retained. 
Therefore rAAV vectors have lost the ability to integrate in a specific manner. Previously, we 
could show that this ability can be restored by providing Rep in trans by co-transducing a Rep 
encoding plasmid and a viral vector coding for a transgene (Huttner et al. 2003). 
To develop specifically integrating rAAV vectors for gene therapy applications we 
decided to link rep-DNA as a polylysine/DNA complex directly to the AAV capsid. After 
infection with such a construct Rep proteins could be expressed and mediate targeted 
integration of the ITR flanked transgene encoded in rAAV in AAVS1 (see Fig. 1). Poly-L-
lysine (PLL) has many advantages that makes it attractive for our approach. PLL is a 
biodegradable cationic polymer with the ability to condense linear, circular and supercoiled 
DNA to compact structures (Gao & Huang 1996). In these PLL/DNA complexes (PLL/DNA) 
the DNA is protected from degradation by nucleases. PLL/DNA have been previously used as 
vector systems for gene therapy applications. Since PLL/DNA alone are not able to transduce 
cells (Curiel et al. 1992; Gao & Huang 1996; Lee & Huang 1996) they had to be coupled to 
ligands, e.g. Ad or transferrin, which mediated receptor attachment, cell entry, and endosomal 
release (Curiel et al. 1992; Wagner et al. 1991; Wagner et al. 1992). After cell entry the PLL 
can be degraded and the DNA is released into the cytoplasm. Moreover, there have been 
reports that PLL might function as nuclear localization signal and transport the DNA directly 
to the nucleus (Gao & Huang 1996). In this study we analyzed the coupling of PLL/DNA 
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complexes to the AAV capsid via a biotin-streptavidin bridge, and studied transduction with 
these constructs. Our results will not only be useful to generate rAAV vectors with the 
potential to integrate site-specifically but also offer a possibility to overcome the limited 
coding capacity of conventional rAAV vectors. 
 
Materials and Methods 
Cell culture. The human cervix epitheloid carcinoma cell line HeLa (ATCC CCL 2; American Type Culture 
Collection, Rockville, Maryland) was maintained as monolayer culture at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM), supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 
mg/ml streptomycin and 2 mM L-glutamine. 
Reagents. Poly-L-lysine (PLL) with a mean molecular weight of 1 kDa (PLL6, P8954), 4 kDa (PLL19, P0879), 
9.8 kDa (PLL47, P6516), 23 kDa (PLL120, P7890), and 47 kDa (PLL225, P2636) was obtained from Sigma-
Aldrich. Steptavidin was purchased from Roche Diagnostics, and Sulfo-NHS-LC-Biotin and Sulfo-LC-SPDP 
from Pierce. Cy5-labeled streptavidin was obtained from Amersham Pharmacia and the Cy3-labeled biotin 
antibody from Jackson Immuno Research Laboratories. 
Plasmids. The plasmid pUC-AV2 contains the full-length AAV2 genome and was constructed as described in 
Girod et al. (1999). The pRC plasmid was constructed as previously described (Girod et al. 1999). Briefly, the 
4.5 kb Xba I-fragment of psub201(+) (Samulski et al. 1987), containing the rep and cap ORFs of AAV was 
subcloned into the Pst I and BamH I sites of pSV40oriAAV (Chiorini et al. 1995).  
The pGFP plasmid is an AAV-based vector plasmid in which the AAV ITR sequences are flanking the 
hygromycin selectable marker gene controlled by the thymidine kinase promoter and the Aequorea victoria 
Green Fluorescence Protein (GFP) gene regulated by the cytomegalovirus promoter. pGFP was generated by 
inserting the Asp718-Not I fragment of pEGFP-N1 (Clontech) into the Asp718-Not I sites of psub/CEP4 (Sal 
invers). psub/Cep4 (Sal invers) is a derivative of psub201(+) (Samulski et al. 1987), which was digested with 
Xba I, blunt ended and ligated to blunt ended 3923 bp Sal I-Nru I-Fragment of pCEP4 (Sal inverse). pCEP4 (Sal 
inverse) differs from pCEP4 (Invitrogen) by inversion of the Sal I (8)-Sal I (1316)-fragment. The adenovirus 
helper plasmid pXX6 (Xiao et al. 1998) was kindly provided by R. Jude Samulski.  
For the construction of pUCGFP the pUC18 plasmid (GenBank accession number L09136) was digested with 
Afl III and Ssp I, blunt ended, and the Sal I fragment of pGFP (containing the cytomegalovirus promoter, the 
GFP gene and the SV40 poly A) was inserted. Similarly, for construction of pRep the blunted Xba I-BsrB I 
fragment of pRC (corresponds to nt 2310 – 3812 of the AAV genome) was inserted into the Afl III/Ssp I 
digested pUC18 plasmid backbone.  
Production of AAV particles. 293 cells were seeded in twenty culture dishes (150-mm diameter), each 
containing 7.5 x 106 293 cells, were cotransfected by calcium phosphate with a total of 37.5 µg of vector 
plasmid (pGFP), packaging plasmid pRC and adenoviral plasmid pXX6 at a 1:1:1 molar ratio. For viruses 
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containing an AAV rep and cap gene, the pUC-AV2 plasmid or mutated plasmid were transfected with pXX6 in 
a 2:1 molar ratio. After 24 hr the transfection medium was replaced by fresh DMEM culture medium containing 
2% FCS and the cells were incubated for 24 h at 37°C and 5% CO2. Thereafter cells were harvested and pelleted 
by low speed centrifugation at 3000xg. Viral particles in the supernatant were precipitated by addition of 
ammonium sulfate and centrifuged (pellet A). The cell pellet was resuspended in DMEM and sonicated. Cell 
debris was spun down at 3700xg for 20 min at 4°C. Supernatant was added to pellet A and further purified by 
ammonium sulfate precipitation. In detail, contaminations were precipitated with 35% ammonium sulfate, after 
centrifugation the viral particles in the supernatant were precipitated in 55% ammonium sulfate. The pellet was 
resuspended in CsCl solution (ρ = 1.37 g/ml) and purified by CsCl gradient centrifugation at 41000 rpm for 
48 h. The main fractions were collected, pooled, dialyzed against HBS (150 mM NaCl, 50 mM Hepes), and 
further purified first by ion-exchange-chromatography and then by affinity-chromatography (heparin-column) as 
described previously (Zolotukhin et al. 1999).  
Evaluation of AAV titers. Particle titers of virus stocks were quantified by dot-blot analysis as described 
(Girod et al. 1999). Briefly, serial dilutions of the AAV preparations were first incubated in 0.5 M NaOH, then 
blotted onto a nylon membrane, and finally hybridized with a random-primer probe specific for gfp or rep by 
standard methods. Infectious particle titers of AAV stocks carrying the rep and cap gene were determined by 
immunofluorescence. 3 x 103 HeLa cells were seeded on 6-well object slides, infected with serial dilutions of 
AAV stocks and co-infected with adenovirus 5 to provide helper functions. 48 h later expression of viral Rep 
proteins was detected with Cy3-labeled 76/3 monoclonal antibody (Cy3 mono-Reactive Dye Pack, Amersham, 
according to the manufacturer’s protocol). Infectious particle titers of the GFP encoding virus stocks were 
determined by infecting irradiated HeLa cells (120 Gy from a 137Cs gamma irradiation source) with serial 
dilutions of the AAV preparation in a 12-well plate. After 48 h cells were harvested and assayed for GFP 
expression by fluorescence-activated cell sorting (FACS).  
Labeling Reactions. Labeling of the AAV capsid with Cy5 was carried out with Fluoro Link Cy5 
monofunctional dye (Amersham Pharmacia, Freiburg). Cy5-labeling of the plasmid pRep was performed with 
Cy5 ULS labeling kit (Amersham Pharmacia, Freiburg) according to the manufacturer’s protocols.  
Biotinylation of AAV. AAV (1 x 1012 genomic particles) in PBS was treated with 180 nmol of NHS-LC-Biotin 
(sulfosuccinimidyl 6-(biotinamido) hexanoat). After incubation for 3 h at room temperature (RT), the virus was 
separated from unreacted biotin by gel-filtration. The biotinylated AAV stock was stored at 80°C. Efficiency of 
this labeling reaction was controlled by ELISA and Western blotting. For the ELISA purified A20 antibody 
(200 ng per well) was coated onto 96-well cell culture plates (Costar) in PBS. After blocking with 6% BSA in 
PBS/0.05% Tween wells were incubated with serial dilutions of biotinylated AAV, and after washing with 
PBS/0.05% Tween incubated with peroxidase-conjugated streptavidin (Dianova, Germany). Colorimetric 
detection was done as described previously (Girod et al. 1999). For Western blot analysis 3 x 103 genomic AAV 
particles were separated on a 10% SDS-PAGE and blotted on nitrocellulose membrane using standard protocols. 
Biotin labeled capsid proteins were visualized with alkaline phosphatase-coupled streptavidin following 
established protocols (Harlow & Lane 1988). 
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Streptavidinylation of polylysine. Streptavidinylation of PLL was carried out as described previously (Wagner 
et al. 1992; Wagner et al. 1990). Briefly, 336 nmol SPDP (heterobifunctional reagent) dissolved in 100% 
ethanol was added to 5 mg streptavidin (Stav) dissolved in HBS (20 mM Hepes, 150 mM NaCl, pH 7.3), 
incubated at RT, and purified by gel-filtration (Sephadex G-25, Pharmazia). 78 nmol of Stav modified with 
192 nmol of dithiopyridine linker was obtained. PLL225 (average chain length of 225 residues) was also 
incubated with SPDP at RT. Then β-Mercaptoethanol was added to reduce the disulfide group, and after gel-
filtration (Sephadex G-25) 60 nmol PLL225 modified with 211 nmol of mercaptoproprionate linker was obtained 
(3.5 linkers for each PLL225 chain). The modified Stav was added and reaction was carried out in HBS at RT 
overnight. The Stav-PLL225 conjugate (Stpl225) was recovered by chromatography on a Mono 2 column 
(Pharmazia) by salt-gradient elution, and extensively dialyzed against HBS pH 7.3. 
Generation of virus-PLL/DNA conjugates. Virus-PLL/DNA conjugates were generated as follows. 
Biotinylated wtAAV (5 x 1010 physical particles) or Ad (5 x 108 physical particles) were treated with 30 ng of 
Stpl225 or Stpl250 in HBS. After a 15 min incubation at RT 300 ng plasmid DNA in 15 µl HBS was added and 
incubated at RT for 15 min. Then 300 or 600 ng PLL (PLL19, PLL47, or PLL120) in 15 µl HBS was added and 
again incubated for 15 min before the solution was used for transfection of HeLa cells (4 x 104 cells per well in 
48-well plates). GFP expression was analyzed 24 or 48 h post infection by fluorescence microscopy and FACS.  
Atomic force microscopy (AFM) of PLL/DNA complexes. For generation of PLL/DNA for AFM indicated 
amounts of poly-L-lysine (PLL6, PLL19, PLL47, or PLL120) were added to 50 µl plasmid DNA (40 µg/ml of 
pUCGFP, pRC, or pXX6) in a total reaction volume of 100 µl 20 mM HEPES and incubated at RT for 30 min. 
All buffer solutions were prepared with ultra-pure water and adjusted to pH 7.3. For samples preparation for 
AFM, freshly cleaved Muscovite mica (Bal-Tec AG, Balzers, Lichtenstein) was used as support, glued to a 
Teflon-laminated mounting. 7 µl of PLL/DNA and 7 µl adsorption buffer (20 mM Hepes / 300 mM KCl) were 
placed on the mica. After 15 min of adsorption, the samples were first gently rinsed with buffer (20 mM 
Hepes / 150 mM KCl) and then with ultra-pure water to remove weakly adsorbed particles, and blown dried 
with nitrogen gas. A commercial AFM (Nanoscope Multimode IIIa, Digital Instruments, Santa Barbara, CA) 
equipped with a 12-µm piezo scanner was operated in standard tapping mode under ambient conditions. V-
shaped silicon nitride cantilevers with normal spring constants around 48 N/m (90 µm length; type NSCH 11, 
Silicon-MDT, Moscow) and resonance frequencies in air of f0 = 420 kHz, and etched silicon probes with 
cantilever length of 125 µm (type di TESP-I, Digital Instruments, Santa Barbara, CA, USA) and resonance 
frequencies between 311 and 393 kHz were used. Images were recorded with a slow scan rate of 1.1 Hz and 
below, and a resolution of 512×512 pixels per image was chosen. 
Single molecule imaging (single virus tracing, SVT). Single molecule imaging was performed in collaboration 
with Prof. Bräuchle at the Center for Nanoscience (LMU München). HeLa cells (3 x 103 per well) were seeded 
on 6-well object slides and infected with AAV constructs as described in the text. Measurements were 
performed as described previously (Seisenberger et al. 2001).  
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Results and Discussion 
Generation of PLL/DNA complexes 
PLL/DNA complexes have been previously used as vector systems for gene therapy, after 
coupling to ligand molecules or viruses like Ad which mediate cellular uptake. PLL/DNA 
coupled to Ad had a size of 100 to 200 nm in diameter. However, AAV has a small capsid of 
only 25 nm in diameter. Therefore, we had to minimize the size of the PLL/DNA, to reduce 
the risk of interference with receptor attachment and cell entry.  
First, we analyzed the impact of plasmid size and PLL molecular weight (chain 
length) on complex formation and size of the PLL/DNA complexes. We therefore used PLL 
of varying chain length (n = 6 - 120) to complex plasmid DNA of various sizes (pUCGFP 
3.8 kb, pRC 8.2 kb, and pXX6 23.0 kb). PLL/DNA-ratios between 0.5 and 3.0 were tested. 
All reactions were carried out in HEPES buffer without the addition of NaCl, because 
PLL/DNA tend to aggregate in saline buffers (personal communication). The dimensions of 
the polyelectrolyte complexes were analyzed by atomic force microscopy (AFM). The AFM 
images of PLL/DNA conjugates formed in HEPES buffer are shown in Figure 2. PLL47 and 
PLL120 efficiently condensed DNA to compact particles even at low PLL/DNA-ratios (ratio 
1.0). In these complexes DNA was protected against DNase I degradation (data not shown). 
The shorter PLL19 also yielded small particles, but there was still free DNA visible. 
Moreover, a high access of PLL19 was necessary to complex DNA and render it resistant to 
DNase degradation. The smallest PLL with a chain length of 6 lysine residues was not able to 
complex plasmid DNA at any PLL/DNA-ratio tested. These results indicate that a minimal 
PLL chain length is needed in order to completely condense plasmid DNA to compact 
structures and render it resistant to nuclease activity. These results are supported by studies of 
Kwoh and colleagues (1999), who also made the observation that shorter PLL (e.g. PLL19) 
did not complex DNA as efficiently as PLL47 or PLL120. In most cases the complexes were 
spherical particles with a size around 30 to 40 nm (Table 1). Only in a few cases, e.g. when 
PLL120 was used for complex formation, could small rods (15 nm width and 80 nm length) 
also be detected. This is in contrast to other studies which observed besides spheres and rods 
mainly donut shaped structures (Kwoh et al. 1999; Wagner et al. 1991). Interestingly, the size 
of the PLL/DNA did not increase significantly with increasing PLL chain length and the 
plasmid size also did not have an apparent influence on particle diameter. Moreover, the 
larger plasmid pRC seemed to form complexes more easily than pUCGFP. In contrast to our 
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findings are the results of Wolfert and Seymour (1996) which have reported a larger 
difference in the average size of PLL/DNA with increasing PLL chain length. This 
discrepancy may reflect differences in the concentration of reactants during complex 
formation. Also the high PLL/DNA-ratio of 5 used in that study may attribute to their 
observation.  
 
 
Table 1. Size of PLL/DNA complexes 
 PLL/DNA ratio pUCGFP pRC pXX6 
PLL6 no complex formation at any ratio n.d. n.d. 
2.0 25 – 45 nm n.d. n.d. 
2.4 30 – 45 nm n.d. 15 – 25 nm PLL19 
3.0 20 – 30 nm n.d. 20 – 25 nm 
1.0 25 – 50 nm 20 – 40 nm 15 – 30 nm 
PLL47 
2.0 25 – 40 nm 15 – 25 nm 20 – 30 nm 
1.0 30 – 50 nm 30 – 45 nm 30 – 50 nm 
PLL120 
2.0 20 – 45 nm 15 – 25 nm 30 – 60 nm 
n.d., not determined 
 
 
Taken together PLL47 and PLL120 were able to efficiently complex plasmid DNA to 
small spherical particles of approx. 20 –45 nm in diameter. At a PLL/DNA-ratio of 1 and 2 
DNA was completely condensed and protected from endonucleases. Such complexes have a 
suitable size for coupling to the AAV capsid. 
 
 
 
 Chapter III 55 
Coupling of PLL/DNA complexes to AAV  
For coupling of PLL/DNA complexes to viral capsids especially adenovirus different methods 
have been described in literature (Wagner et al. 1992). In these settings a biotin-streptavidin 
bridge seemed to work most efficiently. We therefore decided to couple PLL/DNA to the 
AAV capsid also via a biotin-streptavidin bridge. Biotin and streptavidin (Stav) have a strong 
binding affinity (Kd ~ 10-15 mol/l), comparable to a covalent linkage.  
Biotin was covalently linked to AAV and the efficiency of this labeling reaction was 
analyzed by ELISA (data not shown). Western blotting (Fig. 3A) demonstrated that all three 
capsid proteins are accessible for biotinylation. Moreover, this assay also demonstrated that 
the AAV-linked biotin is still able to efficiently bind Stav which is essential for successful 
coupling. To estimate how many biotin molecules are bound per virion, analogous labeling 
reactions were done with Cy5 and AAV, and the Cy5-labeled virus was analyzed by single 
molecule spectroscopy (single virus tracing, SVT) (Seisenberger et al. 2001). These 
experiments revealed that 1 to 2 dye molecules are attached to a single virion in agreement 
with previous observations (Bartlett & Samulski 1998). We therefore assumed that the same 
amount of biotin molecules are bound. Next we tested whether biotinylation interferes with 
AAV infection. HeLa cells were infected with biotinylated AAV and internalized virus was 
detected with an antibody directed against biotin. As figure 3B shows, biotinylated AAV 
efficiently transduces HeLa cells, indicating that this labeling reaction does not interfere with 
the viral infection process. Additionally, infectious titer assays were performed to confirm 
these data. Also in these assays only a minor influence on the transduction efficiency was 
observed, namely a reduction of factor 2 as compared with unmodified virus (data not 
shown).  
For coupling of PLL/DNA to AAV and efficient transduction of these conjugates it is 
essential that the cellular uptake of AAV is not hindered by binding of Stav to the biotinylated 
virus. We therefore analyzed the transduction efficiency of the AAV-biotin/Stav construct 
(AAV-Stav) by SVT. With this method single labeled molecules can be detected on living 
cells in real time. This has the advantage that the fate of single virions can be followed and 
information over unusual behavior compared to unmodified virus can be easily obtained. For 
these experiments biotinylated wtAAV was incubated with a 100 fold molar excess of Cy5-
labeled Stav (StavCy5), the conjugate was purified by gel-filtration (Sephadex G100) to 
remove unbound StavCy5, and HeLa cells were infected (Fig. 4). 380 trajectories were 
measured. In solution, complexes moved with a diffusion coefficient of D = 2.61 µm2/s. This 
56 Chapter III  
is significantly slower than expected when compared with unmodified wtAAV 
(D = 11.2 µm2/s). Two explanations are possible. First, Stav tends to stick to surfaces like 
glass slides. This could mimic a slower diffusion coefficient in these measurements. On the 
other hand, as Stav has four binding sites for biotin, it is possible that more that one 
biotinylated AAV is bound to Stav. In this case the analyzed particles would be bigger and 
therefore also move with a slower diffusion coefficient in solutions than a single virion. From 
the 380 analyzed trajectories 261 had no membrane contact at all. In 96 of the trajectories the 
AAV-Stav complex had membrane contact without entering the cell, and 23 trajectories were 
observed inside the cell. This gives an uptake efficiency of 19%, which is in the range of the 
uptake efficiency observed for wtAAV without Stav (penetration efficiency of 13%) 
(Seisenberger et al. 2001). Two examples of trajectories are given in figure 4A. The images in 
the top row show a Stav-linked virion in contact with the cellular membrane. In the bottom 
row an AAV-StavCy5 that has entered the cell and moves through the cytoplasm is depicted. 
As control StavCy5 without AAV was also analyzed to test whether the observed trajectories 
might have been caused by StavCy5, which possibly had detached from the virion after gel-
filtration. As expected StavCy5 alone was not able to enter the HeLa cells. Additionally, we 
analyzed trajectories of Stav linked to an AAV that carried a Cy3-labeled viral DNA (Fig. 
4B). Similarly, conjugates in contact with the membrane and inside the cell were observed. 
Based on these findings we conclude that AAV-Stav complexes enter the cell as intact 
conjugate with AAV mediating the uptake by interacting with its cellular receptors.  
Taken together, AAV could be easily labeled with biotin without negative effects on 
the viability of the virus. After biotinylation AAV was accessible for Stav binding and the 
AAV-Stav conjugate was able to transduce HeLa cells with an efficiency comparable to the 
unmodified virus. These results provided the basis to couple PLL/DNA complexes to AAV 
via biotin-streptavidin linkage. 
 
Analysis of transduction with AAV-PLL/DNA conjugates 
After the successful linkage between Stav and the biotinylated AAV we set out to analyze the 
coupling of PLL/DNA complexes to virus particles to study transduction. First, we analyzed 
the coupling of PLL/DNA to adenovirus to optimize the reaction parameters in an established 
system. Biotinylated Ad was incubated with streptavidinylated PLL225 (Stpl225), pUCGFP 
plasmid was added and finally PLL47 or PLL120 in a PLL/DNA-ratio of 1 or 2 was added to 
complex the plasmid DNA to compact structures. HeLa cells were infected with these 
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Ad-PLL/DNA conjugates and GFP expression was assayed by FACS analysis 24 h later. As a 
control PLL/DNA complexes alone and virus conjugates generated without Stpl225 were used 
to test for unspecific coupling and/or transduction. The results of this transduction assay are 
given in figure 5. As expected, transduction with PLL/DNA alone was not detectable at any 
ratio tested in agreement with previously published data (Curiel et al. 1991; Curiel et al. 1992; 
Zenke et al. 1990). In contrast, when Ad was incorporated into the virus-PLL/DNA 
conjugates (PLL/DNA-ratio of 1) 31% and 36% of the cells were positive for GFP expression 
when using PLL47 or PLL120, respectively. Unspecific linkage of the PLL/DNA to the virion 
(Fig. 5, w/o Stpl) due to charge interactions showed only a minor effect (5% and 7 %). The 
situation was different when Ad-PLL/DNA were generated with PLL47 or PLL120 at a 
PLL/DNA-ratio of 2. The transduction rate with 16% for PLL47 and 13% for PLL120 was 
significantly lower. Moreover, transduction of conjugates generated without Stpl yielded with 
21% (PLL47) and 16% (PLL120) positive cells even higher transduction rates (Fig. 5). This 
suggests that at a PLL/DNA-ratio of 2 the linkage between the PLL/DNA and the Ad virion 
might be achieved by electrostatic interactions between the positively charged PLL/DNA and 
the negatively charged Ad capsid surface and not exclusively by biotin-streptavidin binding. 
In addition, transduction with Ad-PLL/DNA formed with PLL19 was analyzed. These 
conjugates were not able to transduce HeLa cells at any ratio tested (data not shown) which 
confirmed our observations made in the AFM analysis that PLL19 only insufficiently 
complexes DNA.  
For coupling of PLL/DNA to AAV particles we therefore employed complexes 
generated with PLL120, since virus conjugates generated with PLL120 yielded the highest 
transduction rates. Although PLL/DNA-ratios of 2 resulted in unspecific linkage of 
PLL/DNA complexes to Ad, we decided to use both, ratio 1 and 2, for formation of AAV-
PLL/DNA conjugates. In contrast to Ad AAV has clusters of positive charges on its capsid 
surface (Xie et al. 2002), therefore these unspecific interactions should be rather unlikely to 
occur with AAV.  
First, properties of AAV-PLL/DNA conjugates were analyzed by SVT. Complexes 
were generated as described above and PLL120 was used to complex Cy5-labeld pRep plasmid 
at a ratio of 1 or 2. These complexes were analyzed for diffusion properties and particle size. 
In solution AAV-PLL/DNA moved with a diffusion coefficient of D = 4.58 µm2/s ± 0.03 
(ratio 1) and D = 4.56 µm2/s ± 0.4 (ratio 2). Based thereon the size of the measured 
complexes was calculated to be approx. 60nm for both ratios. We therefore assume that these 
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conjugates consist of one PLL/DNA complex (approx. 30 nm) linked to one AAV particle 
(25 nm) rather than a multimeric aggregate. In a next step HeLa cells were transduced with 
AAV-PLL/DNA and the traces of the conjugates were monitored by SVT. For AAV-
PLL120/DNA (ratio 1) 123 trajectories and for AAV-PLL120/DNA (ratio 2) 108 trajectories 
were analyzed. Several membrane contacts as well as cellular entry of both AAV-PLL/DNA 
were observed (Fig. 6A). Uptake efficiencies, however, were significantly lower than 
measured for AAV-Stav alone, possibly due to steric hindrance of the interaction of AAV 
with its cellular receptor. Nonetheless, these measurements indicate that transduction with 
AAV-PLL/DNA is feasible, although transduction efficiencies need further improvement. To 
confirm these observations transduction by AAV-PLL/DNA containing wtAAV and pUCGFP 
was analyzed by convectional fluorescence microscopy and FACS analysis. For complex 
formation PLL120 was applied in a PLL/DNA-ratio of 1 or 2. HeLa cells were infected and 
48 h later analyzed for GFP expression. As a negative control PLL/DNA complexes alone 
were used. One representative experiment of this transduction assay is given in figure 6B. As 
seen in the FACS image, cells were clearly positive for GFP expression after transduction 
with AAV-PLL120/pUCGFP (ratio 1), while the control transfections were completely 
negative. Thus, it is reasonable to assume that the PLL/DNA have entered cells conjugated to 
AAV, confirming the observations from the SVT experiments. Transduction efficiencies, 
however, were rather low (4% GFP positive cells), and need further improvement before the 
system can be applied in an in vivo model. Studies are therefore currently ongoing to improve 
the transduction efficiency. Additionally, SVT experiments with double labeled AAV-
PLL/DNA, Cy3-labeled viral DNA and Cy5-labeled exterior DNA, are under investigation to 
get a more detailed insight in the uptake route of these constructs.  
Taken together, our study demonstrates for the first time that co-transduction of an 
AAV vector and a transgene cassette attached to the viral capsid is possible. This provides the 
basis for specifically integrating rAAV vectors for the use in human gene therapy. Targeted 
integration of virus vectors is of striking importance for gene therapy applications, especially 
with regard to the risk of insertional mutagenesis of randomly integrating vectors (retroviral 
vector systems). Moreover such vector constructs give the opportunity for many other 
applications: simultaneous gene transfer of regulating factors or more than one therapeutic 
gene would be conceivable. Hence, these vector constructs should develop to become useful 
tools not only to restore site-specific integration of rAAV but also to expand the limited 
coding capacity of commonly used AAV vectors for human gene therapy. 
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Figure 1. Model for specific integration of AAV-PLL/DNA conjugates. Plasmid DNA coding for the viral 
Rep protein is condensed by PLL to compact particles which can be directly linked to the AAV capsid. After 
transduction with these AAV-PLL/DNA conjugates PLL is degraded and the DNA transported to the nucleus. 
After expression of the AAV Rep proteins targeted integration of the ITR flanked transgene cassette takes place.  
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Figure 2. Analysis of PLL/DNA by atomic force microscopy (AFM). (A) Setup of an atomic force 
microscope for tapping mode measurements under ambient conditions. The sample is placed on a piezo-electric 
scanner, a laser beam is focused on the cantilever which is fixed to a cantilever support, and the reflected light of 
the laser beam is captured by a photodetector. The tapping mode operates by scanning a tip, attached to the end 
of a vibrating cantilever, across the sample surface, so that it is in intermittent contact with the surface; the 
cantilever amplitude is maintained constant by altering the vertical position of the piezo-electric scanner. The 
height image is computed from the changes in vertical position. (B) AFM images of PLL/DNA complexes 
formed at a PLL/DNA ration of 2.0. The height of the images is represented by a graded brown-white scale, 
with the white color indicating a height of more than 50 nm (PLL19/pUCGFP), 40 nm (PLL47/pUCGFP), 25 nm 
(PLL120/pUCGFP), 35 nm (PLL47/pRC), 25 nm (PLL120/pRC), and 45 nm (PLL47/pXX6 and PLL120/pXX6) 
above the mica.  
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Figure 3. Biotinylation of AAV. (A) Western Blot analysis of AAV-biotin. Biotinylated capsid proteins (VP1, 
VP2, and VP3) were separated on a denaturing gel and detected by streptavidin labeled with alkaline 
phosphatase (indicated by arrow heads). (B) Fluorescence image of HeLa cells infected with biotinylated AAV. 
AAV-biotin was detected by a Cy3-labeled biotin-antibody 24 h after infection. 
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Figure 4. Analysis of AAV-Stav by single virus tracing. (A) AAV-biotin was coupled to Cy5-labeled Stav 
and HeLa cells were infected. Single AAV-StavCy5 particles were detected by excitation with red laser light of 
633 nm. (B) Similarly, Stav was bound to AAV containing Cy3-labeled DNA and particles were detected by 
green light of 532 nm. 
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Figure 5. Transduction with Ad-PLL/DNA. pUCGFP was complexed with PLL47 or PLL120 at a PLL/DNA 
ratio of 1 or 2 and linked through Stav to biotinylated Ad. These conjugates were used to infect HeLa cells and 
the number of GFP expressing cells was determined by FACS analysis 48 h later. As control conjugates were 
formed without the addition of Stpl or Ad to test for unspecific linkage and transduction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Transduction with AAV-PLL/DNA. (A) HeLa cells were infected with AAV-PLL120/pRepCy5 (ratio 
1) and trajectories were monitored at 633 nm. (B) Infection of HeLa cells with AAV-PLL120/pGFP (ratio 1) and 
analysis of GFP positive cells in comparison to the negative control by FACS. 
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Summary  
The high prevalence of human serum antibodies against adeno-associated virus type 2 (AAV) 
vectors represents a potential limitation for in vivo applications. Consequently, the 
development of AAV vectors able to escape antibody binding and neutralization is of 
importance. To identify capsid domains which contain major immunogenic epitopes, six 
AAV capsid mutants carrying peptide insertions in surface exposed loop regions (I-261, 
I-381, I-447, I-534, I-573, I-587) were analyzed. Two of these mutants, I-534 and I-573, 
showed an up to 70% reduced affinity for AAV antibodies as compared to wild-type AAV in 
the majority of serum samples. In addition, AAV mutant I-587 but not wild-type AAV 
efficiently transduced cells despite the presence of neutralizing antisera. Taken together, the 
results show that major neutralizing effects of human AAV antisera might be overcome by the 
use of AAV capsid mutants. 
 
Introduction 
The human parvovirus adeno-associated virus type 2 (AAV) is a promising vector for human 
somatic gene therapy. Recombinant AAV vectors (rAAV) have many advantages in 
comparison to other vector systems, including the ability to transduce both dividing and non-
dividing cells, long-term gene expression in vitro and in vivo, and the apparent lack of 
pathogenicity. AAV has a broad host range and transduces a wide variety of tissues, including 
muscle, lung, liver, brain, and hematopoietic cells (Fisher-Adams et al. 1996; Flotte et al. 
1993; Halbert et al. 2000; Kaplitt et al. 1994; Russell & Kay 1999; Snyder et al. 1997; Xiao et 
al. 1996). In a potential model of the infection process, AAV first interacts with its primary 
receptor heparan sulfate proteoglycan (HSPG), mediating the attachment of the virions to the 
host cell membrane (Summerford & Samulski 1998). In addition, two types of co-receptors, 
αvβ5 integrin and fibroblast growth factor receptor 1 (FGFR), have been suggested, which 
seem to be involved in the subsequent internalization process (Qing et al. 1999; Summerford 
et al. 1999). However, conflicting results were reported about the contribution of these co-
receptors (Qiu & Brown 1999; Qiu et al. 1999). Following receptor binding, AAV enters the 
cell via a dynamin-dependent endosomal pathway (Bartlett et al. 2000; Duan et al. 1999). 
After acidification of endosomes, viral particles are released into the cytoplasm and rapidly 
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transported to the nucleus, involving microfilaments and microtubules, before they enter the 
nucleus (Douar et al. 2001; Sanlioglu et al. 2000; Seisenberger et al. 2001).  
The capsid of wild-type AAV (wtAAV) harbors a linear, single-stranded DNA 
genome of 4.7 kb, which contains two open reading frames (ORF), rep and cap, flanked by 
the inverted terminal repeats (ITR). The 5’ ORF encodes the four nonstructural proteins 
(Rep78, Rep68, Rep52, and Rep40), which are required for replication, transcriptional control 
and site-specific integration. The three structural proteins, designated VP1, VP2, and VP3, are 
encoded in the 3’ ORF and transcribed from the same promoter (p40) using alternate splicing 
and different translational initiation codons. The small icosahedral capsid, which is only 25 
nm in diameter, is composed of 60 subunits with a relative stoichiometry of about 1:1:8 for 
VP1, VP2, and VP3 (Kronenberg et al. 2001). Recently the atomic structure of AAV has been 
determined (Xie et al. 2002). Each subunit has a β-barrel motif, which is highly conserved 
among parvoviruses. Between the strands of the β-barrel core large loop insertions are found 
that constitute the majority of the capsid surface. These loop insertions seem to interact with 
antibodies and cellular receptors and are highly variable among related parvoviruses. The 
most prominent features of the capsid are the threefold-proximal peaks, which cluster around 
the threefold axis (Xie et al. 2002). Positions on the AAV capsid where interaction with 
HSPG takes place have been determined (Rabinowitz et al. 1999; Wu et al. 2000). They map 
to a positively charged region on the side of the threefold-proximal peaks (Xie et al. 2002). 
Moreover, epitopes of monoclonal antibodies (mAb) which interfere with the AAV infection 
process (A20 and C37-B) have also been mapped to this threefold axis (Wobus et al. 2000; 
Xie et al. 2002). 
Although knowledge is rising about basic AAV biology, there are still obstacles for 
the application of AAV as vector system for somatic gene therapy. One major problem is the 
high prevalence of AAV specific antibodies (Ab) in the human population. 50 to 96% are 
seropositive for AAV Ab, and 18 to 67.5% of them have neutralizing Ab, depending on age 
and ethnic group (Chirmule et al. 1999; Erles et al. 1999; Moskalenko et al. 2000). Especially 
these preexisting neutralizing Ab have profound implications for the application of AAV in 
human gene therapy. Animal experiments have shown that neutralizing Ab greatly reduce or 
even prevent transgene expression after readministration of the vector (Fisher et al. 1997; 
Xiao et al. 2000; Xiao et al. 1996). Different mechanisms for neutralization of viral infections 
have been described (Smith 2001): (i) aggregation of viral particles, (ii) induction of 
conformational changes in the capsid, (iii) interference with receptor attachment, and 
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(iv) inhibition of uncoating due to virion stabilization. In related parvoviruses immunogenic 
sites are formed by highly variable and accessible domains on the capsid surface, which can 
be generally found in the threefold spike region (Fig. 1): on the tip and the shoulder of the 
spike, and between the twofold dimple and the spike (Chapman & Rossmann 1993). In canine 
parvovirus (CPV) two dominant neutralizing epitopes, which are both conformational 
epitopes, are found on the shoulder of the threefold spike (epitope A: residues 93, 222, 224, 
426 and epitope B: residues 299, 300, 302 of VP2) (Strassheim et al. 1994). Similarly, the 
epitopes of two monoclonal neutralizing Ab of B19 parvovirus have also been mapped to the 
threefold spike region (Chipman et al. 1996). Therefore it is possible that immunogenic sites 
of AAV are also located in variable regions of the threefold spike region.  
In a previous study we had generated six AAV capsid mutants bearing an integrin 
specific peptide ligand (L14) insertion at position 261, 381, 447, 534, 573, or 587 of the AAV 
VP1 protein (Girod et al. 1999). These positions were originally selected based on structural 
alignments with the related parvoviruses CPV, B19 and feline panleukopenia virus (FPV), 
with regard to flexible, highly variable, and immunogenic domains of these viruses (see 
Fig. 1; Girod et al., 1999). Indeed, we and others could show that the insertion sites are 
displayed on the capsid surface (Girod et al. 1999; Grifman et al. 2001; Nicklin et al. 2001; 
Wu et al. 2000) and the recently published atomic structure of AAV confirmed the 
localization of the selected positions in surface exposed loop regions (Xie et al. 2002). 
Moreover, binding studies with the neutralizing mAb A20 and C37-B demonstrated that the 
mutations impaired their affinities for the AAV capsid. This indicated that immunogenic 
domains had been affected by the capsid mutations (see Fig. 2a; Wobus et al., 2000). In this 
paper we analyzed these six AAV capsid mutants with polyclonal human serum samples in 
binding and neutralization assays. This allowed us to characterize immunogenic and 
neutralizing regions on the AAV capsid. 
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Results 
AAV antibodies from human serum samples have a reduced affinity for AAV 
insertion mutants 
To determine major antigenic domains involved in the humoral immune response of humans 
against the capsid of AAV, we analyzed the ability of human antisera to recognize AAV 
capsid mutants carrying a 14 amino acid (aa) peptide (L14, QAGTFALRGDNPQG) of the 
laminin fragment P1 inserted at positions 261, 381, 447, 534, 573, or 587 (Girod et al. 1999). 
In a first step, the capsid morphology of the six different VP3 mutants was 
characterized by electron microscopy (EM). All viral preparations showed an EM 
morphology similar to wtAAV and contained predominantly intact particles (data not shown).  
 
 
Table1. Titers of AAV stocks 
Virus stocks Physical particles/ml 1 Infectious particles/ml 2 
wtAAV 4.9 x 1012     7 x 109 
I-261 1.0 x 1012    1 x 104 
I-381 1.0 x 1012   < 1 x 102 
I-447 2.2 x 1012    1 x 106 
I-534 3.5 x 1012   < 1 x 102 
I-573 3.1 x 1012   < 1 x 102 
I-587 2.5 x 1012    6 x 106 
rAAV 2.5 x 1012    3 x 109  
rAAV-587/L14 3.0 x 1011    4 x 106  
rAAV-587/MecA 1.3 x 1012    2 x 108 
1 Physical particle titers were determined by EM for rep/cap-containing particles and by 
dot-blot analysis for recombinant vectors 
2 Determined on HeLa cells by immunofluorescence for preparations containing a rep 
gene, and by FACS analysis for GFP encoding particles 
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The presence of antibodies against wtAAV was then analyzed in 65 human serum 
samples. In an ELISA, 43 out of 65 serum samples (66%) were positive for AAV antibodies. 
Out of these 43 seropositive samples, 29 sera with a high titer of AAV specific antibodies 
(OD>0.6 after subtraction of background) were selected for further analysis. The binding 
affinity of these 29 serum samples to the six AAV insertion mutants (I-261, I-381, I-447, 
I-534, I-573, and I-587) was analyzed in an ELISA and compared to wtAAV. Identical 
numbers of particles of the respective insertion mutants and of wtAAV, as determined by EM 
(Table 1) and confirmed by Western blotting, were coated on the ELISA plates. Binding of 
serum Ab to wtAAV was set as 100%, and the change in serum binding to the AAV mutants 
was determined. Several patterns of interaction of human sera with AAV mutants could be 
distinguished (Table 2). One group of serum samples, designated class A, reacted with all six 
AAV mutants in a way similar to wtAAV (e.g. serum P17, Fig. 2b). This was the case for 10 
out of 29 sera (34%). A second group of serum samples (12 out of 29, 42%), designated class 
B, displayed a reduced binding affinity only to mutants I-534 and I-573 (e.g. serum P37, Fig. 
2b). The average reduction for both, I-534 and I-573, was 31% as compared with wtAAV. A 
third and smaller group of serum samples (7 out of 29, 21%), class C, additionally showed a 
reduced affinity for the other 4 capsid mutants (e.g. serum P26, Fig. 2b). On average, binding 
to these 4 mutants was decreased by 7% (I-381) to 26% (I-447) (Table 2). Nevertheless, 
insertions at positions 534 and 573 reduced binding of serum antibodies to the capsid more 
than insertions at other positions, i.e. by 51% and 45%, respectively (Table 2). Interestingly, 
binding of class C sera to these two capsid mutants was more affected than binding of class B 
serum samples. The observed differences in binding affinity did not significantly change 
when using various serum dilutions.  
Strikingly, mutations at positions 534 or 573 had an effect on the affinity of human 
antisera in 19 of 29 cases. In some cases, serum binding was reduced up to 70%. In 7 serum 
samples, mutations at position 261, 381, 447, or 587 also resulted in a reduced binding 
affinity, albeit to a smaller extent. Based on these findings, we conclude that insertions in 
positions 534 or 573 affected major antigenic determinants of the humoral immune response 
against the AAV capsid. 
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Table 2. 
Binding of seropositive human sera to AAV insertion mutants compared to wtAAV 
Class 1 Serum I-261 I-381 I-447 I-534 I-573 I-587 
A P1 − − − − − −
  P2 − − − − − − 
  P6 − − − − − − 
  P14 − − − − − − 
  P17 − − − − − − 
  P19 − − − − − − 
  P24 − − − − − − 
  P31 − − − − − − 
  P47 − − − − − − 
  P60 − − − − − − 
 Reduction 2      0.3%   " 6.6% 
     0.2% 
  " 4.7% 
     7.5% 
  " 5.5%  
     0.0% 
  " 7.4% 
     3.9% 
  " 8.3% 
   - 2.3% 
  " 5.4% 
B  P5 − − − ? ?? − 
  P7 − − − ??? ?? − 
  P16 − − − ?? ? − 
  P27 − − − ??? ?? − 
  P29 − − − ? ? − 
  P32 − − − − ? − 
  P33 − − − ? ? − 
  P37 − − − ?? ?? − 
  P48 − − − ?? ?? − 
  P51 − − − ? ?? − 
  P53 − − − ? ?? − 
  P59 − − − ? ? − 
 Reduction      3.4%     " 5.8% 
     1.8% 
  " 8.9% 
     9.2% 
  " 5.5% 
    30.9% 
 " 13.5% 
    30.7% 
   " 7.2% 
     4.6% 
  " 3.5% 
C  P3 ? − ?? ??? ??? − 
  P26 ? − ? ??? ??? ? 
  P35 − − ?? ?? ?? − 
   P40 − ?? − ?? ?? − 
  P54 − − ? ??? ?? − 
  P57 ? ? ?? ?? ?? ? 
  P65 ? − ? ??? ??? ? 
 Reduction     12.5%  " 10.6% 
      6.8% 
   " 9.9% 
    25.8% 
  "11.7% 
    51.3% 
 " 10.9% 
    44.8% 
   " 5.0% 
     8.8% 
  " 9.1% 
mAb     A20 ????? ????? − ??? ??? − 
     C37-B ????? − ??? ????? ????? ????? 
The symbols −, ?, ??, ??? and ????? illustrate a reduction in affinity in comparison to wtAAV of 0-14%, 
≥15%, ≥25%, ≥50% and 100%, respectively. 
1 Classification of the serum samples: A, affinity to insertions mutants like to wtAAV; B, reduced affinity to 
I-534 and I-573; C, reduced binding with I-534, I-573 and other capsid mutants 
2 The mean reduction and standard deviation are given 
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Transduction of HeLa cells by rAAV-587/L14 is not inhibited by preexisting 
neutralizing antibodies in human serum samples  
A detailed understanding of major immunogenic domains on the AAV capsid is not only 
important with regard to the binding of serum antibodies to the virus and its subsequent 
neutralization by the immune system, but also with regard to the existence of neutralizing 
antibodies that directly inhibit infection of the target cells by AAV vectors. To analyze the 
interference of different human antisera with AAV transduction, we used a recombinant AAV 
vector carrying the L14 ligand at position 587 (rAAV-587/L14) to determine whether this 
modification would block the neutralizing ability of human antisera. Unfortunately, only 
rAAV-587/L14 could be purified to sufficiently high titers to perform these studies, therefore 
the other insertion mutants were not further tested (Table 1).  
First, we determined the presence of neutralizing Ab in human serum samples. The 43 
positive serum samples were tested in a neutralization assay with an AAV vector coding for 
GFP, which carried the wild-type capsid (rAAV). rAAV was incubated with serial dilutions 
of serum samples prior to transduction of HeLa cells. Thereafter, the number of GFP 
expressing cells was assessed by FACS analysis. Neutralizing titers were defined as the serum 
dilution where transduction was reduced by 50% (N50). Serum samples were considered as 
neutralizing when the N50 was 1:320 or higher. 31 of these 43 serum samples (72%) contained 
neutralizing Ab against AAV, in agreement with previously published data (Erles et al. 1999). 
15 of these 31 serum samples, equally distributed over the above mentioned three 
classes (5 class A, 6 class B, and 4 class C), were selected for further analysis. The effect of 
these serum samples on the transduction of HeLa cells by rAAV-587/L14 as compared with 
rAAV was determined (Fig. 3a). In addition, the neutralizing mAb C37-B and an anti-L14 
serum (see Materials and Methods) were tested. For these experiments identical transducing 
particle numbers of rAAV-587/L14 and rAAV were used. Both vectors were incubated with 
serial dilutions of neutralizing serum samples prior to transduction of HeLa cells. For all 
serum samples tested, transduction by rAAV-587/L14 was 8 up to 64 fold less reduced than 
transduction by rAAV (mean 15 fold). In 13 out of 15 serum samples, transduction by 
rAAV-587/L14 was only slightly impaired, with neutralizing titers of 1:80 or lower, 
demonstrating the ability of rAAV-587/L14 to escape the effects of neutralizing Ab (Fig. 3a). 
Strikingly, rAAV-587/L14 was able to escape the neutralizing Ab in serum P47 at any 
dilution tested, and serum samples P17, P31 and P37 reduced transduction only at a dilution 
of 1:20, where unspecific interactions could not be excluded. Figures 3b and 3c show one 
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representative experiment with serum P35, which completely inhibited transduction by rAAV 
at a 1:80 dilution (Fig. 3b). In marked contrast, transduction by rAAV-587/L14 was not 
affected (Fig. 3c). Only two serum samples (P16 and P48) were able to neutralize 
rAAV-587/L14 transduction efficiently, with a N50 of 1:320. We assume that this was due to 
the high neutralizing Ab content in these serum samples, because transduction by 
rAAV-587/L14 still remained less affected than transduction by rAAV. As an additional 
control, the mAb C37-B was tested. C37-B is a neutralizing Ab that inhibits binding of AAV 
to the host cell (Wobus et al. 2000). It failed to bind I-587 in an ELISA, therefore it should 
not interfere with rAAV-587/L14 transduction. As expected, rAAV-587/L14 transduction was 
not neutralized by C37-B, while rAAV transduction could be totally inhibited by this 
antibody (data not shown). In marked contrast, anti-L14 serum, which was generated against 
the L14 ligand, neutralized rAAV-587/L14 transduction completely at a 1:160 dilution, while 
rAAV transduction remained unaffected (Fig. 3a). To rule out the possibility that these 
observations were due to different numbers of physical particles used for rAAV and 
rAAV-587/L14, we performed additional control experiments, where neutralization assays 
were performed with identical numbers of physical particles for both AAV vectors. For these 
experiments empty capsids were added to the rAAV preparation and neutralization assays 
were performed with three selected serum samples (P16, P17, P35). As seen in figure 3d these 
experiments yielded identical results. Taken together, these results demonstrate that the 
mutant rAAV-587/L14 is able to escape preexisting neutralizing Ab in human serum samples.  
 
Neutralizing sera do not interfere with the L14 mediated tropism of 
rAAV-587/L14 on B16F10 cells 
Insertion of the integrin specific L14 peptide in 587 expands the tropism of AAV to non-
permissive B16F10 cells (Girod et al. 1999). To determine if rAAV-587/L14 was able to 
retain its ability to infect the target cell line B16F10 via the inserted ligand L14 in the 
presence of neutralizing antisera, we performed additional experiments with selected serum 
samples. rAAV-587/L14 was incubated with serial dilutions of P35 serum before transduction 
of irradiated B16F10 cells. After 72 hours GFP expression was measured. rAAV-587/L14 
efficiently transduced B16F10 cells despite incubation with P35 at a 1:80 dilution, whereas 
anti-L14 serum completely inhibited transduction at this dilution (Fig. 4b and c). When 
testing P37 and P26, the same neutralizing titers as determined on HeLa cells were obtained 
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(data not shown). These findings showed that the AAV L14 targeting vector could escape 
neutralizing antibodies in human sera while retaining its retargeting ability.  
 
The ability of rAAV-587 to escape neutralizing sera does not depend on the 
inserted L14 ligand 
To exclude that the escape from neutralizing antisera was caused by a specific ligand, we 
tested another insertion mutant, rAAV-587/MecA that carries a 7 aa ligand (GENQARS) at 
position 587. This mutant has been selected by AAV-display on Mec1 cells and efficiently 
transduces Mec1 cells and primary B-cells from chronic lymphocytic leukemia patients in a 
receptor specific manner (Perabo et al. 2003). rAAV-587/MecA and rAAV were incubated 
with the serum P35 before Mec1 cells were infected. Transduction of Mec1 cells by 
rAAV-587/MecA was not affected by the neutralizing Ab of serum P35 (1:80 dilution). In 
contrast, rAAV transduction was almost completely inhibited by this serum (Fig. 5). 
Experiments with other neutralizing serum samples provided identical results (data not 
shown). In additional control experiments the neutralizing Ab A20 was able to inhibit 
transduction by rAAV-587/MecA, while C37-B had no effect (data not shown). 
Taken together, the results demonstrate that the insertion of different heterologous 
ligands at position 587 allows escape from preexisting neutralizing antibodies. Targeting 
properties of these vectors are retained in these capsid mutants, even in the presence of 
neutralizing antisera. 
 
Discussion 
Because of the high prevalence of antibodies against AAV in the population, it is essential in 
gene therapy approaches to understand the immunogenic determinants of the AAV capsid and 
to develop strategies to circumvent antibody binding and neutralization of AAV vectors. In 
this study, we analyzed six AAV capsid mutants (I-261, I-381, I-447, I-534, I-573, and I-587) 
with a 14 aa peptide ligand inserted into the VP3 part of the capsid protein to identify 
immunogenic domains on the AAV capsid. We showed that peptide insertions at position 534 
or 573 reduced binding of human antisera in 66% of the analyzed samples, indicating that 
these regions might be preferentially recognized by human AAV antibodies. In addition, we 
analyzed AAV vectors modified at position 587 to study the potential of AAV capsid mutants 
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to escape the neutralizing effects of human antisera with regard to the transduction efficiency. 
We demonstrated that these modified vectors were able to escape neutralizing Ab in human 
antisera without losing their ability to infect cells via the targeted receptors. In marked 
contrast, transduction of AAV carrying the unmodified capsid was significantly reduced or 
inhibited. These findings demonstrate that the insertion of peptide ligands at site 587 reduces 
the ability of AAV antibodies in human blood to neutralize the transduction by rAAV vectors. 
The atomic structures of related parvoviruses like CPV, FPV and B19 have been 
resolved during the past decade and antigenic sites have been determined (see Fig. 1) 
(Agbandje et al. 1994; Chang et al. 1992; Chapman & Rossmann 1993; Chipman et al. 1996; 
Strassheim et al. 1994 ; Tsao et al. 1991). At the beginning of our studies the capsid structure 
of AAV was still unknown. Alignments of these related parvoviruses with AAV led to 
hypothetical models of the AAV capsid, and systematic mutagenesis helped to map functional 
sites on the capsid (Girod et al. 1999; Rabinowitz et al. 1999; Wu et al. 2000). Based on our 
structural alignments, six sites on the AAV capsid, selected with regard to flexible, highly 
variable loops and immunogenic domains of related parvoviruses (Fig. 1), were identified to 
accept the insertion of an integrin specific RGD ligand (L14, QAGTFALRGDNPQG) (Girod 
et al. 1999). Immunological analysis demonstrated the surface localization of the inserted L14 
peptide (Girod et al. 1999). Characterization of other AAV serotypes revealed that the 
selected positions are also within highly variable regions amongst these serotypes (Chiorini et 
al. 1999). The recent unveiling of the atomic structure of AAV (Xie et al. 2002) broadly 
confirmed the flexible loop regions predicted by our initial structural model (Girod et al. 
1999). When mapping the six insertion sites used in this report on the three-dimensional 
structure of AAV, they can all be found on the capsid surface within the threefold spike 
region (Fig. 6).  
The high prevalence of AAV specific Ab causes substantial problems for human gene 
therapy. Different approaches have been pursued to map epitopes on the AAV capsid. 
Moskalenko et al. (2000) used small overlapping peptides (15aa) spanning the VP1 protein 
and human antisera to screen the AAV capsid protein by peptide scan. They identified several 
linear epitopes presented on the capsid surface, amongst them sites mapping to I-261 and I-
447. However, some of the identified peptides might block Ab binding unspecifically or 
might not be displayed on the capsid surface (Wobus et al. 2000; Xie et al. 2002). Moreover, 
conformational epitopes cannot be identified by this method. Wobus et al. (2000) used murine 
mAb, which recognize conformational epitopes (D3, C37-B, C24-B, and A20), to identify 
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epitopes on the AAV capsid. Immunological analysis of these mAb with our six AAV 
insertion mutants helped mapping the epitopes of these antibodies on the AAV capsid and 
provided information about regions involved in receptor attachment. However, murine mAb 
cannot mimic the polyclonal Ab repertoire after an infection in humans. We therefore 
analyzed the ability of human antisera to recognize the six AAV insertion mutants in order to 
determine major antigenic domains of AAV involved in the humoral immune response. By 
using an ELISA we could demonstrate that the majority of the serum samples had a reduced 
affinity towards two insertion mutants, I-534 and I-573. Although at 39 aa distance from each 
other on the primary sequence, these sites are found in close proximity in the assembled 
capsid, on the side of the peaks at the threefold rotation axis (Xie et al. 2002). These data 
indicate the importance of the threefold-proximal peak region in the recognition by the 
humoral immune response, as it has been already shown for B19 or CPV (Chapman & 
Rossmann 1993; Chipman et al. 1996; Strassheim et al. 1994). It remains to be elucidated 
whether these mutations interfere with Ab binding directly or indirectly due to structural 
changes in adjacent regions.  
Insertions at sites 261, 381, 447, and 587 affected binding of serum Ab only in a 
minority of serum samples. This was surprising, because mutations at position 261, 381 and 
587 abolished binding of murine mAb A20 and C37-B, respectively (Fig. 2a). Moreover, 
amino acids corresponding to positions 261, 381, and 447 are part of major antigenic 
determinants in CPV (Strassheim et al. 1994). Different explanations are conceivable for this 
minor effect of these mutations on human Ab binding. (i) It is possible that epitopes, 
especially linear epitopes, which are adjacent to these insertion sites, have not been affected 
and that they are responsible for the remaining reactivity of serum Ab towards these mutants. 
(ii) In contrast to CPV, AAV residues 261 and 381 are located in the valley between two 
peaks of the threefold symmetry axis and this region might be less accessible for Ab binding, 
or less relevant for inducing a humoral immune response. (iii) Serum samples consist of a 
polyclonal Ab population. Thus, epitopes which only induce a weak Ab response might not 
have been detected in this binding assay, although they were affected by the mutations. For 
the same reason, we also did not expect a complete inhibition of binding of the polyclonal Ab, 
as observed with the monoclonal Ab A20 with I-261, I-381 and C37-B with I-534, I-573, and 
I-587. (iv) In addition, the specificity of Ab for a given antigen is dependent on the B-cell 
repertoire, T-cell repertoire and the major histocompatibility complex (MHC), and is 
therefore different at the species and individual level. Murine Ab generated against viral 
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antigens may differ in their targeted sequences to those generated in humans. All six 
insertions are directly at or close to the spike region. It is likely that in individuals the 
positions of the major antigenic determinants of AAV are different. In this case differences in 
human serum Ab binding were only seen if the major antigenic determinants were close to the 
spike region. This might also explain why serum samples of class A displayed no reduced 
affinity for any of the six insertion mutants, but this does not exclude that different mutants 
would impair binding of these sera. Consequently, it is reasonable to assume that other 
immunogenic determinants exist which have not been identified so far.  
For the in vivo application of AAV, epitopes which interact with neutralizing 
antibodies are of particular importance. We therefore investigated the ability of AAV vectors 
with insertion of different peptide ligands at 587 to escape the preexisting neutralizing Ab in 
human antisera. Such vectors have previously been shown to efficiently retarget infection to 
wtAAV resistant cells (Girod et al. 1999; Nicklin et al. 2001). Moreover, Wu and colleagues 
(2000) demonstrated that this 587 region is involved in binding to the primary attachment 
receptor HSPG. 15 neutralizing serum samples were analyzed for their ability to neutralize 
rAAV-587/L14 transduction in comparison to rAAV. Strikingly, rAAV-587/L14 could escape 
the neutralizing effects exerted by 13 of the 15 neutralizing serum samples and efficiently 
transduced various cell lines. The targeting properties of rAAV-587/L14 were not affected, 
and escape could also be observed with a second ligand (MecA) that differed in size and 
sequence, demonstrating that the escape did not depend on the particular L14 insertion. 
Unfortunately, infectious titers of the other insertion mutants were not sufficient to perform 
neutralization assays. However, it is possible that insertion of different peptide ligands yield 
higher infectious titers, as they strongly depend on the peptide size and sequence (compare 
MecA with L14, and see also Shi et al. 2001). Nevertheless, our results do not allow the 
conclusion that insertions at position 587 are the only site to generate mutants, which are able 
to escape the neutralizing effects of human antisera. 
It seems contradictory that I-587 only slightly impaired binding of serum samples in 
the ELISA, while it had such strong effects on the neutralizing capacity of human antisera. At 
least two explanations are possible: Human sera consist of a polyclonal Ab population 
directed against various epitopes on the AAV surface, but only a small amount of these Ab 
are capable of neutralizing AAV transduction. Therefore, in an ELISA these neutralizing Ab 
may not have a noticeable effect on the overall Ab binding, whereas they inhibit virus 
transduction in a neutralization assay. The three dimensional structure of AAV shows that the 
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sites for interaction with the viral receptor HSPG are located within the peaks of the threefold 
axis, proximate to residue 587 (Wu et al. 2000; Xie et al. 2002). Furthermore, the neutralizing 
Ab C37-B, which inhibits binding of wtAAV to the host cell, has its epitope adjacent to this 
site in the assembled capsid. Therefore this region seems to be critical for receptor binding. It 
is very likely that neutralizing Ab are preferentially directed against this region and explains 
why the action of these Ab is affected by insertions at this region (Wobus et al. 2000; Xie et 
al. 2002). Whether these modifications directly interfere with neutralizing epitopes at position 
587 or antigenic determinants on neighboring loops within the threefold proximal peaks are 
affected due to conformational changes remains to be elucidated. Additional experiments with 
point mutations or small deletions at 587, for example, could help to map such epitopes in the 
587 region more precisely. Another explanation is that neutralizing Ab, which have been 
generated against the wtAAV capsid, only block the wt capsid mediated transduction. After 
insertion of a targeting ligand at position 587 the virus mutant can use a different uptake route 
than wtAAV, which does no longer depend on HSPG binding (rAAV-587/L14 via the 
integrin receptor) (Girod et al. 1999; Nicklin et al. 2001). Therefore it is supposable that these 
neutralizing Ab cannot block the interaction of these AAV mutants with alternative cell 
surface receptors. Of course, these explanations are not mutually exclusive, and due to the 
complexity and various mechanisms of the neutralization process other explanations are also 
possible. However, it is reasonable to assume that capsid modifications at position 587 might 
not only allow to alter the tropism of AAV but also to generate immune escape variants. All 
data presented here were generated in vitro. Animal experiments are now needed to 
corroborate the utility of this concept, not only with regard to neutralization by antibodies, but 
also with regard to transduction efficiency and tropism of these genetically modified vectors. 
In addition, in vivo studies could help to clarify if insertion of such peptide ligands possibly 
promotes the generation of new epitopes, e.g. the fusion region where the peptide is inserted. 
Taken together the results indicate that the threefold-proximal peaks on the AAV 
capsid are major antigenic determinants for antibody binding as well as for neutralization of 
AAV transduction. Moreover, our results demonstrate that modifications at site 587 could 
allow to generate AAV vectors with the ability to escape neutralization by human antisera. 
Importantly, these modified vectors retain their ability to transduce specific target cells. These 
findings might be useful for the production of AAV vectors suitable for repeated 
administration in human gene therapy.  
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Materials and Methods  
Cell culture. HeLa, 293 and B16F10 cells were grown in Dulbecco´s modified Eagle’s medium (DMEM) 
supplemented with 10% heat-inactivated fetal calf serum (FCS), penicillin (100 U/ml), streptomycin 
(100 µg/ml), and L-glutamine (2 mM). Mec1 cells were cultivated in Iscove’s modified DMEM supplemented 
with 10% FCS, penicillin-streptomycin and L-glutamine. Cells were maintained at 37°C in a 5% CO2 humidified 
incubator. 
Antibodies and human serum samples. B1, A20 and C37-B were generated by immunization of mice with 
purified AAV capsid proteins and synthetic peptides, respectively, followed injection with AAV empty particles 
(Wistuba et al. 1995; Wobus et al. 2000). 76/3 was generated by immunization with purified Rep protein as 
described (Wistuba et al. 1995). Serum against the L14 ligand was obtained after immunization of a rabbit with 
L14 peptide (Girod et al. 1999). Serum samples from human patients were kindly provided by the Klinikum 
Großhadern in Munich, Germany.  
Plasmids. The plasmid pUC-AV2 contains the full-length AAV2 genome and was constructed as described in 
Girod et al. (1999). The plasmids pI-261, pI-381, pI-447, pI-534, pI-573, pI-587 are derived from pUC-AV2, 
with the L14-encoding sequence inserted in the cap gene. The AAV2-based helper plasmids pRC, pRC(I-587) 
and pRC(587/MecA) contain the AAV2 Rep and Cap encoding regions but lack the viral ITRs (Girod et al. 
1999; Perabo et al. 2003). pRC(587/MecA) contains a DNA fragment coding for the MecA ligand inserted 
between amino acid position 587 and 588. The pGFP plasmid is an AAV2-based vector plasmid in which the 
AAV ITR sequences flank the hygromycin selectable marker gene controlled by the thymidine kinase promoter 
and the enhanced GFP gene regulated by the cytomegalovirus promoter (Ried et al. 2002). The adenovirus 
helper plasmid pXX6 (Xiao et al. 1998) was kindly provided by R. J. Samulski. 
Preparation of virus stocks. The AAV stocks were generated as described previously (Ried et al. 2002) with 
the following modifications. 293 cells seeded at 80% confluence in plates with 15 cm of diameter were 
transfected with a total of 37.5 µg of vector plasmid (pGFP) and packaging plasmid (pRC for wt capsid, 
pRC(I-587) for L14 carrying capsid, and pRC(587/MecA) for MecA carrying capsid) and adenoviral plasmid 
(pXX6) at a 1:1:1 molar ratio. For viruses containing an AAV rep and cap gene, the pUC-AV2 plasmid or 
mutated plasmids were transfected with pXX6 in a 2:1 molar ratio. After 48 h cells were collected and pelleted 
by centrifugation. Cells were resuspended in 150 mM NaCl, 50 mM Tris-HCl (pH 8.5), lysed by repeated 
freeze-thaw cycles, and treated with Benzonase (50 U/ml) for 30 min at 37°C. Cell debris was removed by 
centrifugation and the supernatant was loaded onto an iodixanol gradient as described (Zolotukhin et al. 1999). 
After centrifugation at 69,000 rpm for 1 h at 18°C the AAV containing iodixanol phase was harvested. 
Evaluation of AAV titers. Particle titers of virus stocks containing rep/cap were determined by electron 
microscopy and confirmed by Western blotting. Electron microscopy was performed at the DKFZ (Heidelberg). 
Iodixanol gradient purified viral particles were adsorbed onto Formvar-carbon-coated copper grids and 
negatively stained with uranyl acetate. Titers were calculated in comparison to a known viral standard (Grimm et 
al. 1999). Western blot analysis was performed to confirm the titers obtained by electron microscopy. Equal 
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numbers of AAV particles were separated on a 10% SDS-PAGE and blotted on nitrocellulose membrane using 
standard protocols. Capsid proteins were detected by B1 hybridoma supernatant, followed by incubation with a 
peroxidase-coupled secondary antibody (Sigma) and visualized by enhanced chemiluminescence (Pierce). For 
recombinant vectors encoding the GFP protein genomic titers were quantified by dot-blot analysis as described 
(Girod et al. 1999). Briefly, serial dilutions of the AAV preparations were first incubated in 2 M NaOH, then 
blotted onto a nylon membrane, and finally hybridized with a random-primed gfp probe by standard methods. 
Infectious particle titers of the GFP encoding virus stocks were determined by infecting irradiated HeLa cells 
(100 Gy from a 137Cs gamma irradiation source) with serial dilutions of the AAV preparation in a 12-well plate. 
After 48 h cells were harvested and assayed for GFP expression by fluorescence-activated cell sorting (FACS). 
Infectious titers on B16F10 and Mec1 cells were performed accordingly by co-infection with adenovirus 5 
(AdV). Titers of AAV stocks carrying the rep and cap gene were determined by infection of HeLa cells after 
AdV co-infection and detection of the viral Rep proteins with Cy3-labeled 76/3 monoclonal antibody (Cy3 
mono-Reactive Dye Pack, Amersham, according to the manufacturer’s protocol). 
ELISA. Identical particle amounts (5 x 108 per well) as determined by electron microscopy of wtAAV und 
AAV insertion mutants were coated onto microtiter plates (MaxiSorp; Nunc Nalgene International) in PBS 
overnight at 4°C. After blocking with 3% BSA / 5% sucrose in washing buffer (PBS/0,05% Tween 20) wells 
were incubated with A20- or C37-B-hybridoma supernatant or human serum diluted 1:50 to 1:400 in blocking 
buffer for 1h at room temperature. After washing wells were incubated with a biotin-conjugated anti-human or 
anti-mouse secondary antibody (Dianova) diluted in washing buffer for one hour. Detection and quantification 
was performed as described previously (Girod et al. 1999). Serum samples were considered as seropositive for 
AAV antibodies when the measured OD was 0.2 or higher at a 1:300 dilution after subtraction of background. 
Neutralization Assay: HeLa cells or B16F10 cells were seeded in 96-well plates (5 x 103 cells per well) and 
infected with AdV (MOI 5) or irradiated 2 h prior to infection with AAV, respectively. Identical transducing 
particle numbers (MOI 5) of rAAV (wt capsid) and rAAV-587/L14 were incubated with serial dilutions (1:10 to 
1:1200) of human serum in PBS for 2 h at 4°C in a total volume of 30 µl. Before addition of the AAV/serum-
mixture medium was replaced by 100 µl of fresh medium. 48 h (HeLa) or 72 h (B16F10) after infection GFP-
positive cells were detected by FACS analysis and fluorescence microscopy. Similarly, Mec1 cells were seeded 
at 5 x 104 cells per well, infected with AdV followed by infection with rAAV or rAAV-587/MecA, which had 
been incubated with serial dilutions of human serum as described above. The neutralizing titers are expressed as 
the dilution at which transduction was 50% reduced compared to the positive control (N50). Serum samples were 
considered as neutralizing when the N50 was 1:320 or higher. 
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Figure 1. Map of major antigenic regions in CPV, FPV and B19. The triangle represents one asymmetric 
subunit of the CPV major capsid protein. The positions of the 5-fold, 3-fold and 2-fold symmetry axis are 
indicated. The amino acid positions of major antigenic determinants in CPV (red), B19 (yellow) and FPV (blue) 
are given (aligned to the CPV capsid protein) (Chapman & Rossmann 1993).  
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Figure 2. Binding of A20 and C37-B monoclonal antibody (a) and human serum samples (b) to wtAAV and 
AAV capsid mutants as determined by ELISA. Microtiter plates were coated with identical particle amounts of 
wtAAV and AAV insertion mutants and incubated with hybridoma supernatants of either A20 or C37-B mAb or 
with serum samples of human patients as described in Materials and Methods. Binding of antibodies to wtAAV 
was set at 100% (y axis). Each experiment was repeated independently at least three times; the figure shows the 
mean values and standard deviations (indicated by the error bars).  
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Figure 3. Neutralization assay on HeLa cells. (a) Neutralizing antibody titers against rAAV and rAAV-587/L14. 
Serial dilutions (1:10 – 1:1200) of 15 neutralizing human serum samples were analyzed on HeLa cells. As 
control, rabbit serum directed against the inserted L14-ligand (α-L14) was tested. The neutralizing titers (N50) 
are expressed as the dilution at which transduction was 50% reduced compared to the positive control. rAAV (b) 
and rAAV-587/L14 (c) were incubated with serum P35 (1:80) prior infection of HeLa cells. GFP expression was 
monitored 48 hours post infection. (d) Empty capsids were added to rAAV to adjust physical particle numbers. 
The N50 was determined as described above. 
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Figure 4. Neutralization assay on B16F10 cells. Infection of irradiated B16F10 cells with rAAV-587/L14 alone 
(a) or after co-incubation with P35 serum (b) or anti-L14 serum (c) at a 1:80 serum dilution. Cells were analyzed 
for GFP expression after 72 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of neutralizing antisera on rAAV-587/MecA transduction. (a) After infection with adenovirus, 
Mec1 cells were infected with rAAV (top row) and rAAV-587/MecA (bottom row) alone (positive control) or 
after co-incubation with serum P35 at a 1:80 dilution (+ serum P35). Note that more physical particles were used 
for rAAV to achieve similar transduction. (b) FACS analysis of rAAV (top row) and rAAV-587/MecA (bottom 
row) incubated with serum P35 (red line) in comparison to their positive controls (blue line). GFP expression 
was determined 48 hours post infection. 
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Figure 6. Model of the AAV major capsid protein according to the atomic structure by Xie et al. (2002) (taken 
from The Protein Data Bank). The sites of insertion are marked with arrows. 
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Summary 
Adeno-associated virus (AAV) is a promising vector for human somatic gene therapy. 
However, its broad host range is a disadvantage for in vivo gene therapy, because it does not 
allow the selective tissue- or organ-restricted transduction required to increase the safety and 
efficiency of the gene transfer. Therefore, increasing efforts are being made to target AAV-2 
based vectors to specific receptors. The studies summarized in this review show that it is 
possible to target AAV-2 to a specific cell or organ. So far, the most promising approach is 
the genetic modification of the viral capsid. However, the currently available AAV-2 
targeting vectors need to be improved with regard to the elimination of the wild type AAV-2 
tropism and the improvement of infectious titers. The creation of highly efficient AAV-2 
targeting vectors will also require a better understanding of the transmembrane and 
intracellular processing of this virus. 
 
Introduction 
The development of safe and efficient gene transfer vehicles is critical for the success of gene 
therapy. One of the most promising viral vectors is based on adeno-associated virus type 2 
(AAV-2), a member of the parvovirus family. AAV-2 was discovered as a co-infecting agent 
during an adenovirus outbreak, without any apparent pathogenicity contributed by AAV-2 
(Blacklow 1988; Blacklow et al. 1968a; Blacklow et al. 1971). Until now, no human disease 
caused by AAV-2 has been detected. Moreover, AAV-2 seems to be protective against bovine 
papillomavirus and adenovirus mediated cellular transformation (Hermonat 1989; Khleif et al. 
1991; Mayor et al. 1973). AAV-2 does not induce cytotoxic effects and does not elicit a 
cellular immune response as commonly seen with other viral vectors (Carter & Samulski 
2000). Finally, AAV-2 has the unique potential to integrate site specifically into the q-arm of 
human chromosome 19 (Kotin et al. 1990; Samulski et al. 1991).  
AAV-2 has a broad tissue tropism infecting diverse organs such as brain, liver, 
muscle, lung, retina and heart muscle. This makes AAV-2 attractive for in vitro gene transfer 
into various tissues (Carter & Samulski 2000). AAV-2 vectors are now successfully used for 
in vivo gene transfer (Monahan & Samulski 2000; Tal 2000). However, the studies reported 
so far clearly demonstrate that clinically relevant gene expression can be reached only in the 
liver, unless vectors are administered directly into the target tissue or organ. These results 
emphasize the need for a targeting of AAV vectors in order to overcome the apparent 
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limitations of a broad tissue tropism. In addition, the targeting of AAV vectors would also 
enhance the safety and efficiency of AAV-mediated gene transfer in vivo. Therefore, 
increasing efforts are being made to retarget AAV-2 based vectors to specific receptors and to 
generate selective, tissue- or organ-restricted vectors. The studies summarized in this review 
show that it might become possible to target AAV-2 to a specific cell type or organ. However, 
the targeting vectors still need to be optimized by a further reduction of the wild type AAV-2 
tropism, or with an increase in infectious titer. With the rapidly increasing knowledge about 
the functional domains on the AAV-2 capsid involved in receptor binding and subsequent 
steps of transmembrane and intracellular processing of the virion, we feel justified to predict 
that the creation of highly efficient AAV-2 targeting vectors will become possible in the near 
future. 
 
Organization of the AAV-2 genome  
AAV-2 is a single stranded, replication deficient non-enveloped DNA virus (Rivadeneira et 
al. 1998) composed of an icosahedral protein capsid and a viral genome of 4680 nucleotides. 
The AAV-2 genome encodes the two large open reading frames rep and cap. It is flanked at 
both ends by the 145 bp inverted terminal repeat sequences (ITR). The ITRs are required for 
encapsidation of the viral genome and seem to have enhancer and/or weak promoter activity. 
They are besides the viral Rep proteins necessary for the site specific integration of wild type 
AAV-2 and for the rescue of proviruses. The 5’ open reading frame rep encodes four 
overlapping, multifunctional proteins (Rep78, Rep68, Rep52 and Rep40) controlled by two 
different promoters (Balague et al. 1997). The large Rep proteins (Rep78 and its splice variant 
Rep68) are controlled by the p5 promoter and are necessary for viral DNA replication, 
transcriptional control and site-specific integration. Rep52 and its splice variant Rep40 are 
known as small Rep proteins. They are transcribed from the p19 promoter and play an 
essential role in the accumulation of single-stranded progeny genomes used for packaging. 
The 3’ ORF cap accommodates the three capsid proteins VP1 (90 kDa), VP2 (72 kDa) and 
VP3 (60 kDa), which form the 60 subunits of the AAV-2 viral capsid at a 1:1:20 ratio 
(Rabinowitz & Samulski 2000). They are controlled by the p40 promoter, share the same stop 
codon, but differ due to alternative splicing and different initiation codons resulting in 
progressively shorter proteins from VP1 to VP3. All three capsid proteins are necessary for 
the generation of infectious particles, although capsids are formed in the absence of VP1 
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(Hermonat et al. 1984; Smuda & Carter 1991; Tratschin et al. 1984). The capsid assembly 
itself occurs in the nucleus (Wistuba et al. 1997; Wistuba et al. 1995). The N-terminus of VP2 
contains a nuclear localization sequence by which it transports VP3 into the nucleus (Hoque 
et al. 1999; Ruffing et al. 1992). The encapsidation of the AAV-2 genome probably takes 
place in the nucleoplasm and Rep-tagged DNA seems to initiate packaging by interaction 
with capsid proteins (Dubielzig et al. 1999).  
If rep and cap are provided in trans on a helper plasmid, 96% of the wild type AAV 
genome can be removed and replaced by a transgene, because the ITRs are the only cis 
elements necessary for the generation of recombinant AAV (rAAV) (Carter & Samulski 
2000). The protocols to generate high-titer and highly purified viral preparations have 
undergone continuous improvements (Hermens et al. 1999; Summerford & Samulski 1999). 
Until now, rAAV is commonly produced by transfection of a vector plasmid (containing the 
ITR flanked transgene) and a helper plasmid (encoding Rep and Cap) into HeLa or 293 cells, 
followed by superinfection with adenovirus type 5. Alternatively, a triple transfection of 
vector-, helper- and an adenovirus helper plasmid can be used (Ferrari et al. 1997; Girod et al. 
1999; Grimm & Kleinschmidt 1999; Xiao et al. 1998). After harvesting, AAV is purified 
using iodixanol or CsCl gradient ultracentrifugation and/or chromatography (Chiorini et al. 
1995; Hermens et al. 1999; Summerford & Samulski 1999; Zolotukhin et al. 1999). After 
purification, infectious particle titers of AAV-2 of >109/ml are easily reached, which is 
sufficient for most in vitro and in vivo experiments, at least in smaller rodents. However, 
when it comes to larger animals or human beings in clinical applications, it is strongly 
desirable to enhance the target specificity of AAV vectors by receptor retargeting in order to 
reduce the amount of vector particles to be administered. 
 
Three-dimensional structure of AAV-2  
Recently, Xie et al. (2002) were able to determine the atomic structure of AAV-2 to a 3-Å  
resolution by x-ray crystallography. Like Kronenberg et al. (2001), who investigated empty 
capsids by electron cryo-microscopy and icosahedral image reconstruction, Xie et al. (2002) 
observed substantial differences in the surface topology between AAV-2 and other 
parvoviruses. The inner surface of the AAV-2 capsid is composed of a jelly-roll β-barrel 
motif, comprising two antiparallel β-sheets. This motif is common in virus capsids and has 
also been described for other parvoviruses like canine parvovirus (CPV) (Tsao et al. 1991), 
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feline panleukopenia virus (Agbandje et al. 1993), minute virus of mice (Agbandje-McKenna 
et al. 1998), or the human parvovirus B19 (Agbandje et al. 1994). However, the interstrand 
loops located between the strands of the core β-barrel have quite different structures in the 
different parvoviruses and are the regions responsible for interactions with antibodies and 
cellular receptors. The most prominent features of the AAV-2 surface topology are the 
“threefold-proximal” peaks. These peaks cluster around each icosahedral three-fold rotation 
axis. Unique for AAV-2 is that neighboring subunits interact intimately at this threefold axis. 
Additional, but more modest interactions were also observed for residues in the HI, BC and 
EF loop of neighboring subunits. The threefold proximal peaks are mainly formed by a so 
called GH loop. This loop is missing in densoviruses (insect parvoviruses) and is structurally 
different in CPV. This loop is, as expected, mainly involved in binding to the primary 
receptor of AAV-2 (see below) and contains the epitope recognized by the neutralizing 
antibody C37-B. Moreover, the most promising position for the insertion of receptor specific 
peptides (amino acid position 587) is also located in this loop.  
Before the characterization of the three-dimensional structure of the AAV-2 capsid, 
potential insertion sites as well as the determination of antibody and receptor binding regions 
were identified by epitope mapping, mutagenesis studies of capsid proteins, as well as 
sequence alignments of AAV-2 and related parvovirus including other serotypes. Although it 
was possible by these approaches to determine functional relevant regions of the AAV-2 
capsid, the now solved three dimensional structure will accelerate this process by using a 
more rational, structure-based approach. 
 
Infectious pathway of wild type AAV-2  
A successful viral infection is a multistep process starting with the attachment of the virus to 
the cell surface, followed by viral uptake, intracellular trafficking and - in most of the cases - 
nuclear transport and deposition or replication of the viral genome in the cell nucleus. In the 
current model of infection of permissive cells by AAV-2 (Fig. 1A), AAV-2 first binds to 
heparan sulfate proteoglycans (HSPG), which act as primary or attachment receptors 
(Summerford & Samulski 1998). Since all adherent cells express glycosaminoglycans on their 
surface, this offers a simple explanation for the broad tropism of AAV-2. No distinct heparin 
binding motif was identified so far in the AAV-2 capsid. However, Wu et al. (2000) mapped 
two regions involved in HSPG binding by alanine substitution and insertion of the 
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hemagglutinin (HA) epitope YPVDVPDYA. These regions encompass amino acids 509 to 
522 and 561 to 591 (in VP3) and are clustered around the threefold-proximal peaks (Xie et al. 
2002). The alanine substitution mutant 585-RGNR-588 and the HA insertion mutant 591 for 
example are located on the side of the threefold-proximal peak facing the valley, which 
separates this peak from its neighbor, whereas the alanine insertion mutant 509 is on the floor 
of the valley. The other two mutants generated by Wu et al. were mapped at the base of 
(alanine substitution at 561-565) and underneath (HA insertion at 522) the peak facing the 
twofold axis. Xie et al. assume that mutations in the regions underneath the peak (insertion at 
522 and 519; see (Rabinowitz et al. 1999) are not directly affecting the HSPG binding of 
AAV-2.  
Two types of AAV-2 co-receptors have been identified, αvβ5 integrin and fibroblast 
growth factor receptor 1 (FGFR1) (Bartlett et al. 2000; Qing et al. 1999; Summerford et al. 
1999). It is postulated that FGFR1 enhances the attachment process (Bartlett et al. 2000; 
Qing et al. 1999). Antibodies against αvβ5 integrin do not interfere with cell binding but 
inhibit endocytosis. Therefore, αvβ5 integrins seem to be required for endocytosis of AAV-2 
(Sanlioglu et al. 2000), which is mediated mainly by clathrin-coated pits (Bartlett et al. 2000; 
Duan et al. 1999). This endocytotic process and the subsequent steps are still poorly 
understood. However, it is possible to assume that like for adenovirus αv integrin clustering 
facilitates the localization of virus particles to coated pits (Wang et al. 1998). This could then 
activate the endocytosis in which Dynamin, a 100 kDa cytosolic GTPase, is involved. 
Although the precise function of Dynamin in vesicle formation remains controversial (Marks 
et al. 2001; Sever et al. 2000), it is known that it is essential for scission of newly formed 
vesicles from the plasma membrane (Marks et al. 2001). For AAV-2 it was shown that the 
introduction of a dynamin mutant results in the decrease of AAV mediated transduction 
(Bartlett et al. 2000; Duan et al. 1999), although it was not possible to abolish the AAV-2 
infection. However, Sanlioglu et al. (2000) assumed that the binding to the integrin could 
have an additional effect, which is the activation of Rac1. They propose that Rac1 activation 
results in the stimulation of phosphoinositol-3 kinase (PI3K) which facilitates the 
rearrangements of microfilaments and microtubuli. These rearrangements are necessary to 
support the initiation of the intracellular movements of AAV-2 to the nucleus after 
endocytosis. The release of AAV-2 from the endosome at the early-to-late endosomal 
transition requires a low endosomal pH (Bartlett et al. 2000; Douar et al. 2001). As with other 
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Figure 1. Infectious pathway of wild type AAV-2. (A) Schematic representation of AAV entry and endocytic 
trafficking in HeLa cells as seen by fluorescent and confocal laser microscopy. Following binding to heparan 
sulfate proteoglycans (HSPG) on the cell surface (1), AAV is rapidly internalized via clathrin-coated pits (2) 
through a process involving αvβ5 integrin, Dynamin and Rac1. Following endocytosis, the activation of 
phosphatidyinositol-3 kinase seems to support the initiation of the intracellular movement. After acidification 
AAV is released from the endosome into the cytoplasm (3), where it is found in a perinuclear localization (4). 
Then AAV slowly enters the nucleus (5) probably via nuclear pore complexes (NPC). (B) Trajectories of single 
AAV-Cy5 particles analyzed by single virus tracing (Seisenberger et al. 2001). The traces show single diffusion 
virus particles at different times. In this figure three examples of the various stages of the AAV-2 infection are 
visible (diffusion in the cytoplasm after cell entry (1), diffusion in solution (2) and touching at the cell 
membrane (3)). Normal diffusion with a diffusion coefficient of D = 7.5 µm2/s could be measured for AAV-2 
outside the cell (2). A deceleration of AAV-2 near the cell could be observed. When approaching the cell, a 
repetitive touching of the cell membrane by AAV-2 occurred, which was interrupted by short diffusion path in 
the vicinity of the cell surface (3). Inside the cell AAV movements using direct motion, anomalous and normal 
diffusion were observed (1). This method also allowed to distinguish between free viruses and AAV inside 
endosomes by calculating the diffusion constants of the particles traced by SVT.  
 
viruses (Marsh & Helenius 1989), the low pH is likely to induce conformational changes of 
key viral proteins necessary for a successful endosomal release or nuclear entry. Interestingly, 
the unique region of VP1 contains a potential phospholipase A2 (PLA2) domain (Girod et al. 
2002), which might be involved in this process. PLA2 inactivating point mutations do not 
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influence the capsid assembly, packaging, cell binding or entry of AAV-2, but delay the onset 
and reduce the amount of early gene expression. Thus, the PLA2 activity in the N-terminus of 
VP1 may be required for the exit of AAV-2 from the endosome and the transfer of the viral 
genome to the nucleus. A PLA2 domain with similar function has been found in porcine 
parvovirus (Zadori et al. 2001). The destiny of AAV-2 after this endosomal release is mostly 
unclear. Some studies have observed a perinuclear accumulation of AAV-2 particles (Bartlett 
et al. 2000), before the virus slowly enters the nucleus, probably via nuclear pore complexes. 
However, the perinuclear accumulation of AAV-2 observed by conventional fluorescent and 
confocal laser microscopy may suffer from some methodological shortcomings such as 
interference effects and the cellular virus overload required for these conventional imaging 
studies (see next paragraph). These results need to be confirmed by independent methods. 
The development of a novel technique, called single virus tracing (SVT), which allows 
the visualization of an individual virus in a living cell with high spatial and temporal 
resolution, may permit a more detailed analysis of specific steps of the cellular infection 
(Seisenberger et al. 2001) (Fig. 1B). Using this technique Seisenberger et al. observed AAV-2 
movements towards the cell surface, which were followed by repetitive touching and short 
diffusion paths in the vicinity of the cell surface. The touching events were clearly visible as 
short periods of immobility at the cell surface, with a mean touching time of tt = 62 ms. Inside 
the cell, three different kinds of AAV-2 movements were observed in the cytoplasm and the 
nuclear area, namely directed motion, anomalous diffusion and normal diffusion. In 
agreement with the current model of AAV-2 infection, most virions followed a normal 
diffusion in endo- or lysosomal particles. However, in marked contrast to the above findings 
with conventional microscopic techniques, neither a nuclear accumulation nor a slow 
penetration of the nuclear membrane was observed by SVT. Interestingly, the total time 
measured for membrane penetration, trafficking through the cytoplasm and entry into the 
nuclear area was much shorter than determined by other methods (Seisenberger et al. 2001). 
By this new method it was for example possible to detect at least one Cy5- labeled AAV-2 in 
the nucleus of 50% of the cells 15 minutes after adding virus to the cells.  
 
 
 Chapter V 95 
AAV serotypes other than AAV-2 
Most AAV vectors are based on the AAV-2 serotype, as it was the first serotype from which 
an infectious clone was available (Samulski et al. 1982). 50 to 96% of the population is 
seropositive for AAV-2. Five additional primate AAV serotypes (AAV-1, -3, -4, -5, and 6) 
have been characterized at the nucleotide level (Chiorini et al. 1999; Chiorini et al. 1997; 
Muramatsu et al. 1996; Rutledge et al. 1998). With the exception of AAV-6, which has a 
>99% amino acid homology with AAV-1, all serotypes show a significantly different amino 
acid sequence of the capsid proteins, which is most prominent in VP3 (Rabinowitz & 
Samulski 2000) and most obvious for AAV-4 and -5. It remains to be determined how these 
differences influence the binding of neutralizing antibodies, viral tropism and intracellular 
processing.  
An investigation of the humoral immunity against AAV performed with a cohort of 85 
human volunteers revealed that none of the sera contained neutralizing antibodies against 
AAV-5, although neutralizing antibodies against AAV-1 and AAV-2 were detected in 19 and 
25% of the sera, respectively (Hildinger et al. 2001). Furthermore, neutralizing antibodies 
against AAV-4 or AAV-5 do not cross-react (Rabinowitz & Samulski 2000). Serum from 
mice immunized with AAV-2 vectors did not neutralize AAV-6 infection in tissue culture, 
neutralized AAV-3 only partially, but inhibited AAV-2 almost completely (Halbert et al. 
2000). Similar results were obtained with AAV-3 used for immunization. Serum from AAV-6 
immunized animals did not cross-react with AAV-2 or AAV-3 and neutralized the infection 
by AAV-6 only weakly.  
In AAV-2, VP3 is responsible for receptor binding and therefore mainly determines 
the viral tropism. Differences in this region should result in a different receptor usage and 
viral tropism. Therefore it was not unexpected that AAV-4 and AAV-5, which show the 
lowest similarity to AAV-2, use α2-3 O-linked (AAV-4) and N-linked (AAV-5) sialic acid 
for cell binding (Kaludov et al. 2001) instead of HSPG. AAV-6, which has a homology of 
about 60% to AAV-4 and –5 (Bantel-Schaal et al. 1999), also binds to sialic acid (Seiler et al. 
2002), whereas AAV-3 binds to HSPG.  
The various AAV serotypes show a different tissue or cell tropism (Halbert et al. 
2000; Hildinger et al. 2001; Rabinowitz et al. 2002). AAV-1 is more efficient than AAV-2 for 
the transduction of skeletal muscle (Xiao et al. 1999). AAV-3 is superior for the transduction 
of megakaryocytes (Handa et al. 2000). Compared to AAV-2, AAV-5 and AAV-6 infect 
apical airway cells more efficiently (Halbert et al. 2001; Zabner et al. 2000). 
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AAV-2, -4 and -5 transduce cells of the central nervous system, but differences in the 
distribution and the target cell types exist (Davidson et al. 2000). It can be anticipated that 
further work on AAV serotypes will result in the identification of all domains involved in 
receptor binding and uptake. This knowledge will be very useful for the creation of AAV 
retargeting vectors.  
 
Receptor Targeting of AAV 
In principle, at least two different strategies are possible to achieve a receptor targeting of 
AAV (Cosset & Russell 1996):  
1. Indirect targeting: In contrast to wild type (Fig. 2A) the interaction between the viral 
vector and the target cell is mediated by an associated molecule (e.g. a glycoside 
molecule or a bispecific antibody) which is bound to the viral surface and interacts with a 
specific cell surface molecule (Miller 1996) (Fig. 2B).  
2. Direct targeting: The cell specific targeting of the vector is mediated by a ligand which 
is directly inserted into the viral capsid (Walter & Stein 1996) (Fig. 2C).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Possibilities of targeting viral vectors. Viral vectors with wild type tropism (A) show a direct 
binding of structural capsid components to the cell surface receptor. In targeting vectors, the virus-cell 
interaction is mediated by a molecule associated with the capsid (indirect targeting, B) or by a ligand directly 
inserted into the capsid (direct targeting, C).  
wild type tropism (A)
direct modification of viral capsid (C)
 cell virus interaction
by associated molecule (B)
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For indirect targeting (Fig. 2B) it is not necessary to know the three-dimensional structure of 
the viral surface if high affinity viral surface binding molecules such as monoclonal 
antibodies are available. For this strategy, the stability of the interaction of the virus with the 
intermediate molecule and the efficiency by which the complex is generated are rate limiting. 
In addition, the intermediate molecules must bind to cell-specific receptors which allow the 
uptake and correct intracellular processing of the virus.  
A combination of two important parameters is required for the successful generation 
of a targeting vector by direct modifications of the capsid (Fig. 2C). The first parameter is a 
good choice of the insertion site to ensure that packaging of the mutant remains efficient and 
the inserted ligand is exposed on the virus surface. Until now two alternative strategies have 
been used for AAV-2 to identify candidate positions for insertion of heterologous ligand: a) 
sequence alignment between AAV-2 and other parvoviruses for which the X-ray crystal 
structure is known (Girod et al. 1999; Grifman et al. 2001); b) a systematic, insertional 
mutagenesis of the whole AAV-2 capsid (Rabinowitz et al. 1999; Shi et al. 2001; Wu et al. 
2000). The second important parameter is the choice of the targeting peptide. It is difficult to 
predict the secondary structure of the ligand inserted into the AAV capsid. Therefore, the 
ligand should be structure-independent and not too large to avoid the destabilization of the 
entire capsid. Moreover, the ligand should be cell type specific. Finally, the ligand-receptor 
complex should be internalized in a way that allows an efficient transport of the virus and the 
release of the viral DNA in the cell nucleus. 
Both approaches and a combination thereof have been used to retarget AAV-2 and 
will be described in the following paragraphs (Bartlett et al. 1999; Girod et al. 1999; Grifman 
et al. 2001; Nicklin et al. 2001; Ried et al. 2002; Shi et al. 2001; Wu et al. 2000; Yang et al. 
1998). 
 
Targeting by bispecific antibodies  
The feasibility to target AAV-2 using a bispecific antibody which mediates the interaction 
between virus and target cell (Fig. 2B) was first shown by Bartlett et al. (Bartlett et al. 1999). 
The antibody used was generated by a chemical cross-link of the Fab arms of monoclonal 
antibodies against the αIIbβ3 integrin (AP-2 antibody) and the intact AAV-2 capsid (A20 
antibody, see (Wistuba et al. 1995). The major ligand for αIIbβ3 is fibrinogen, which becomes 
internalized via endocytosis. Therefore, AAV-2 targeted to this integrin was expected to 
become internalized via receptor-mediated endocytosis, similar to wild type virus. This 
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targeting vector transduced MO7e and DAMI cells, which are not permissive for wild type 
AAV-2 infection (70-fold above background). In contrast, a 90% reduction in AAV-2 
transduction was seen on cells negative for the targeting receptor. It remains to be determined 
whether this reduction was due to steric hindrance or some other mechanism. Another issue 
that remains to be resolved is the stability of the virus-bispecific antibody complexes in vivo. 
 
Targeting by insertion of single chain antibodies or receptor specific ligands at 
the N-terminus of VP proteins  
The first attempt to alter the tropism of AAV-2 was described by Yang et al. (Yang et al. 
1998). They inserted a single-chain antibody against human CD34, a cell surface molecule 
expressed on hematopoietic progenitor cells, at the 5’-ends of VP1, VP2 and VP3. Using a 
transcription and translation assay, they could express all three different single-chain 
fragment variable region (scFv)-AAV-2 capsid fusion proteins. However, they failed to 
produce detectable rAAV-2 particles when using either all three scFv-VP fusion proteins or 
one scFv-VP fusion with two other unmodified capsid proteins. Therefore they had to use all 
three wild type AAV-2 capsid proteins for the packaging process in addition to one of the 
three single scFv-VP fusion proteins. Using this procedure, intact viral particles could be 
generated which were able to infect HeLa cells and showed an increased transduction of 
CD34 positive KG-1 cells. Although this approach provided the first demonstration that 
targeting of AAV-2 by direct modification of the capsid is possible, the virus titers (1.9x102 
transducing units/ml on KG-1) were extremely low. Moreover, very heterogeneous viral 
preparations consisting of an unknown mixture of chimeric, targeting and wild type AAV-2 
particles were produced.  
Wu et al. (2000) inserted the hemagglutinin (HA) epitope YPVDVPDYA into the N-
terminal regions of VP1, VP2 and VP3 and the C-terminus of the cap ORF. They observed 
that the insertion of this and other epitopes at the N termini of VP1 (VPN1) and VP3 (VPN3) 
and at the C-terminus of the cap ORF (VPC) resulted in either no detectable particles (VPN3 
and VPC), or in a 2-3 log decrease of infectious and physical particle titers. In agreement with 
Yang et al. (1998), only the insertion at the N-terminus of VP2 (amino acid position 138) was 
tolerated (Wu et al. 2000). Moreover, exchanging the HA epitope by the serpin receptor 
ligand KFNKPFVFLI (Ziady et al. 1997) resulted in a 15-fold higher infection of the lung 
epithelial cell line IB3 than by wild type AAV-2. The fact that the N-terminal insertion of 
different peptides is tolerated in VP2 and allows targeting, albeit at low efficiency, probably 
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reflects the exposure of the N-terminus of VP2 at the viral surface analogous to CPV 
(Chapman & Rossmann 1993; Weichert et al. 1998). This assumption was further confirmed 
by the results of Shi et al. (2001), who inserted a 6 amino acid peptide (TPFYLK) from 
bovine papillomavirus (BPV) at position 139 and were able to detect this epitope on the 
capsid surface by monoclonal antibodies against BPV. In addition, the insertion of a 10 amino 
acid peptide (HCSTCYYHKS) derived from the human luteinizing hormone (LH) increased 
the infection efficiency of a LH-receptor positive human ovarian adenocarcinoma cell line, 
OVCAR-3.  
 
Targeting of rAAV-2 vectors by insertion of ligand coding sequences into the 
capsid genes  
The first successful demonstration that a genetic capsid modification (direct targeting) can be 
used to retarget AAV-2 was described by Girod et al. (1999). A sequence alignment of AAV-
2 and CPV identified 6 sites (amino acid positions 261, 381, 447, 534, 573, 587) that were 
expected to be exposed on the surface of the virus capsid and to accept the insertion of a 
ligand without disrupting functions essential for the viral life cycle (Fig. 3A).  
At these positions the sequence for the 14 amino acid peptide L14 
(QAGTFALRGDNPQG) was inserted into the capsid gene. The L14 peptide contains the 
RGD motif of the laminin fragment P1, is the target for several cellular integrin receptors, and 
can also serve as a viral receptor (Aumailley et al. 1990; White 1993). In addition no specific 
secondary structure is required for the recognition of the receptor (Aumailley et al. 1990). All 
six mutants could be packaged with an efficiency similar to wild type AAV-2 and showed an 
intact capsid structure in electron microscopy images (Grimm et al. 1999; Wistuba et al. 
1997). Using an ELISA with an anti-L14 polyclonal antibody it was demonstrated that the 
L14 epitope was exposed at the viral surface when inserted at amino acid positions 261, 381, 
447, 573 and 587. In a cell binding assay insertion mutants I-447 and I-587 were able to bind 
B16F10 (mouse melanoma) and RN22 (rat swannoma) cell lines, which did not bind to and 
were not infected by wild type AAV-2. An efficient transduction of B16F10 cells was 
observed using the AAV insertion mutant I-587 expressing Rep or β-galactosidase.  
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Figure 3. L14 peptide insertion sites in the AAV2 capsid. (A) Schematic diagram of the two open reading 
frames rep and cap. Cap encodes the three capsid protein VP1, VP2 and VP3. Sites of the L14 insertion 
described by Girod et al. (1999) are marked by arrows (numbers are the amino acid positions N-terminal of the 
insertion). (B) Sequence of L14 and flanking amino acids at the different insertion sites tested. The insertion 
mutant I-587 displayed the L14 peptide on the surface and was able to retarget the mutant to the mouse 
melanoma cell line B16F10 (Girod et al. 1999) (numbering starts at the start codon of VP1). 
 
The same site, 587, was also successfully used for the insertion of an endothelial 
specific peptide isolated by phage display, and allowed the generation of an AAV-2 mutant 
able to infect endothelial cells such as human umbilical vein endothelial cells (HUVEC) and 
human saphenous vein endothelial cells (HSVEC) (Nicklin et al. 2001). In contrast to wild 
type AAV-2 infection, the infection of the endothelial specific cells by the mutant was not 
blocked by heparin, showing that the infection did not depend on HSPG. Moreover, heparin 
binding studies showed that the mutant was not retained in a heparin column, in contrast to 
wild type AAV-2. The specificity of the binding was shown by infection studies using 
different non-endothelial specific cell lines such as HepG2. Furthermore, the mutant seemed 
to follow an intracellular route different from wild type AAV-2 since compounds such as 
bafilomycin A2 (an inhibitor of endosomal acidification) did not inhibit transduction. Taken 
together, all studies underline the potential value of the 587 site of the AAV-2 capsid, which 
is positioned at the tip the GH loop (Xie et al. 2002) for the generation of cell-specific AAV-2 
REP
CAP
A
261        381         447     534    573 587
VP1 VP2
YNNHLYKQIS SQSGASNDNHQAGTFALRGDNPQG261
IDQYLYYLSR TNTPSGTTTQQAGTFALRGDNPQG447
VPQYGYLTLN NGSQAVGRSSQAGTFALRGDNPQG381
B
SHKDDEEKFF PQSGVLIFGKQAGTFALRGDNPQG534
EIRTTNPVAT EQYGSVSTNLQAGTFALRGDNPQG573
SVSTNLQRGN RQAATADVNTQAGTFALRGDNPQG587
 Chapter V 101 
vectors by the direct targeting approach (Fig. 2C) (Girod et al. 1999; Nicklin et al. 2001; Ried 
et al. 2002). 
This strategy was successfully repeated by Grifman et al. (2001). They also used a 
sequence alignment approach to identify potential targeting sites of the AAV-2 capsid by 
expanding their comparisons to parvoviruses other than CPV and to the other AAV serotypes 
(AAV-1, -3, -4 and -5). They identified identical regions to Girod et al. (1999), and finally 
used sites 448 and 587 for their studies. Grifman et al. (2001) inserted the Myc epitope and a 
CD13 (NGR receptor expressed on angiogenic vasculature and in many tumor cell lines) 
specific peptide with the sequence NGRAHA, identified by phage display. The insertion of 
NGRAHA at 587 allowed a cell-specific targeting to different cell lines (KS1767 (Kaposi 
sarcoma) and RD (rhabdomyosarcoma)). Interestingly, deletion of the 6 amino acids 
(GNRQAA) at position 586-591 resulted in the loss of heparin binding, whereas the insertion 
of the targeting peptide (NGRAHA) restored the heparin binding ability. Taking into account 
that HSPG has a negative charge, the R at position 588 might have an essential role for HSPG 
binding.  
For a systematic characterization of functional domains of the AAV capsid proteins, 
Wu et al. (2000) constructed 93 mutants at 59 different positions on the AAV-2 capsid by site 
directed mutagenesis. They identified several putative regions, which were involved in HSPG 
binding and/or exposed on the capsid surface, with the potential to tolerate the insertion of a 
ligand. These positions were 34 (in VP1), the N-terminus of VP2 (138), as well as 266, 328, 
447, 522, 553, 591, 664 (in VP3). Although all VP3 insertion mutants were precipitated by an 
antibody against the inserted HA epitope, only 266, 447, 591 and 664 were still infectious. 
For insertion mutant 522, this could be explained by the loss of the HSPG binding ability 
(Rabinowitz et al. 1999; Wu et al. 2000). For the other mutants, a simple explanation is 
lacking. Wu et al. (2000) tested only the position 34 in the VP1 sequence (FVFLI 
substitution) and the N-terminus of VP2 (KFNKPFVFLI insertion) for targeting of AAV-2 to 
IB3 cells via serpin receptor. It was shown that targeting and infection was possible. In this 
approach the N-terminal VP-2 insertion mutant was 15-fold and the VP1 mutant 
approximately 62-fold more infectious than the wild type. In both cases, the insertions were 
placed outside the potential HSPG binding regions. Therefore it was not surprising that the 
transduction of the target cells by these mutants was blocked by heparin, suggesting that the 
serpin-tagged mutants continued to use HSPG as primary receptor and used the serpin 
receptor as alternative (co-)receptor. 
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Using insertional mutagenesis, Shi et al. (2001) also tried to identify positions in the 
AAV-2 capsid which might tolerate the insertion of heterologous peptide ligands. In addition 
to the VP2 N-terminal insertion mutants mentioned above, mutants with insertions into the 
capsid sequences were generated. These mutants contained either an insertion of two amino 
acids (TG or AG) or of longer epitopes derived from the bovine papillomavirus (BPV; 
TPFYLK), from the human luteinizing hormone (LH; HCSTCYYHKS) or a cyclic RGD-
containing peptide specific for αv integrins (4C-RGD, CDCRGDCFC). None of these mutants 
were tested for retargeting, but three important observations were made: 
1. Five different capsid regions were identified which allowed the surface display of the 
BPV peptide ligand. These were 139 (N-terminus of VP2), 161 (in the VP2 region), 459, 
584 and 587 (in the VP3 region). The positions 139 and 587 confirmed earlier results 
(Girod et al. 1999; Wu et al. 2000). The other sites remain to be tested for functional 
targeting, because the surface display of a ligand alone is a prerequisite but not sufficient 
for a ligand dependent infection by the virus mutant (Girod et al. 1999).   
2. The scaffold sequences flanking the heterologous ligand are important for epitope 
display, HSGP binding ability and titers. Using for example the amino acids ALS to flank 
the BPV ligand inserted at 584 resulted in mutants that showed surface display of the 
epitope, HSPG binding and the production of infectious particles. In contrast, LLA and 
GLS used as scaffold sequences did not allow the production of infectious particles and 
reduced the surface display of the BPV ligand. In contrast, the GLS scaffold sequence 
was better tolerated than LLA or ALS at position 587. 
3. Not every ligand, even if comparable in length, is tolerated at a specific insertion site. Shi 
et al. (2001) inserted either the BPV or the LH ligand both flanked by the GLS scaffold 
sequences at site 459 and observed that the BPV ligand (a 6 amino acid insertion) 
generated fully infectious particles, whereas the insertion of the 10 amino acid LH 
peptide created non-infectious virus particles. Our laboratory made similar observations 
when trying to insert multimers of the L14 sequence at position 587: larger insertions at 
position 587 resulted in a decrease of the packaging efficiency although the insertion of a 
34 amino acid containing the Z34C protein A domain of Staphylococcus aureus (see 
below) was well tolerated. These results show that the maximal length of the peptide 
tolerated at this position depends on the sequence itself. The precise determinants of this 
phenomenon are unknown.  
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Generation of universal targeting vectors by combining two principles of vector 
targeting 
Inspired by an earlier attempt for Sindbis virus (Ohno et al. 1997), we tried to use a general 
targeting vector using a truncated 34 amino acid peptide, Z34C, from protein A of 
Staphylococcus aureus (Ried et al. 2002). Protein A recognizes and binds the Fc part of 
immunoglobulins (Ig), but not the variable Ig domain, which therefore remains free to bind 
the antigen. Z34C is derived from the protein A subunit B, which encompasses 56 amino 
acids and binds the Fc portion with a dissociation constant of about 10-50 nM (Sinha et al. 
1999). A 38 residue truncation of this domain, selected by phage display, was further 
truncated and stabilized by insertion of disulfide bonds and showed thereafter a dissociation 
constant of 20 nM. The insertion of Z34C at position 587 in the AAV-2 capsid (587Z34C) 
resulted in a 10-fold decrease of packaging efficiency in comparison to wild type AAV-2. In 
contrast, the combination of the insertion with a 9 amino acid deletion (587∆9Z34C) resulted 
in a packaging efficiency similar to wild type AAV-2. Electron microscopy and A20-ELISA 
revealed a wild type capsid morphology for both mutants, although empty capsids were 
observed 3-fold more frequently. Interestingly, the wild type tropism of the Z34C insertion 
mutants decreased by 4 orders of magnitude, in agreement with the results of Nicklin et al. 
(2001). The insertion of Z34C at position 587 allowed a functional expression of the IgG 
binding domain, as shown by binding studies using various antibodies. Interestingly, the 
capsid mutant 587Z34C bound antibodies more efficiently than 587∆9Z34C, maybe because 
the binding domain was less accessible with the 9 amino acid deletion. In agreement, Grifman 
et al. (2001) showed that a substitution at 587 was less efficient than an insertion. Coupling 
587Z34C virus with antibodies against CD29 (β1-integrin), CD117 (c-kit-receptor) or 
CXCR4 resulted in a specific, antibody mediated transduction of hematopoietic cell lines. No 
transduction could be detected without antibody, whereas the targeted infection was blocked 
with soluble protein A or with IgG molecules. In addition, no inhibition of transduction by the 
targeting vector was observed with heparin, demonstrating that the interaction of the 
587Z34C mutants with the natural AAV-2 receptor HSPG was not essential for infection or 
transduction. Taken together, this targeting approach shows that a universal AAV targeting 
vector can be generated and loaded with different targeting molecules to transduce the desired 
cells via specific receptors. However, this approach leaves room for improvement, since the 
titers obtained with these vectors were relatively low. 
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Future prospects: understand the infectious biology of AAV 
To efficiently retarget AAV vectors a better understanding of the infectious biology of AAV 
will be required. This includes the virus-cell surface interactions, mechanisms of uptake, 
endosomal processing and release, nuclear transport and mechanisms leading to gene 
expression. The structure determination of the AAV-2 capsid (Xie et al. 2002) will 
tremendously enhance our knowledge of the location and function of different capsid 
domains. 
The identification of HSPG as primary attachment receptor for AAV-2 was an 
important achievement. However, no distinct binding motif within the capsid has been 
identified so far, despite some useful information presented in the work of Rabinowitz et al. 
(1999) and Wu et al. (2000). Such knowledge will be required to specifically modify the 
natural viral tropism of AAV-2. 
A better understanding of the intracellular processing of AAV targeting vectors is 
essential, because AAV targeting vectors may be transferred into a cellular compartment from 
which they will never be released, or in which they will be processed in ways preventing 
nuclear processing or gene expression. Therefore, the success of creating AAV targeting 
vectors will ultimately depend on our ability to unveil the detailed mechanisms of AAV 
transport and processing. Some pieces of the puzzle are already known (Bartlett et al. 2000; 
Sanlioglu et al. 2000; Seisenberger et al. 2001), but the picture is not complete. With regard to 
this, single virus tracing (Seisenberger et al. 2001) will be a very important tool to understand 
which receptors and cellular compartments need to be used to efficiently re-target AAV. On 
the other hand, the technique of AAV vector targeting will help to uncover some important, 
basic functions of AAV capsid proteins, as well as mechanisms of the infectious biology of 
AAV.  
The third important issue is the identification of the optimal ligand or targeting 
receptor. For the genetic modification strategy chosen by our group, the length and sequence 
of the ligand are critical, as the insertion of a peptide may result in profound alterations of the 
three-dimensional capsid structure. One possibility of overcoming this problem is the 
combination of the insertion with one or more deletions. Another possibility is the insertion of 
a sequence which is able to form its own secondary structure, for example a loop closed by a 
cysteine bridge.  
These difficulties are overcome when using an antibody or another bridging molecule 
to mediate the interaction between the viral surface and the target cell. However, this 
 Chapter V 105 
approach will encounter other problems such as the stability of the virus-ligand complex, 
limitations to scale up the vector production, and steric hindrance of the virus uptake by large 
virus-ligand complexes. To identify new ligands, phage display has been proven to be a valid 
approach. However, the ligand sequences are selected in an architectural context that is 
different from that of the final vector. This means that once inserted in the context of AAV, 
they could destabilize the capsid structure (resulting in low packaging efficiency) or lose their 
biological properties (resulting in low infectious titers). To overcome these difficulties the 
screening for new “retargeting” peptides to be inserted might be done more efficiently in the 
context of the AAV capsid itself (vector display), where a pool of randomized peptide 
sequences is inserted into the capsid sequence and the viral pool is then screened directly on 
the target cells (Perabo et al. 2003). The exciting results obtained by this approach together 
with the rapid advance of our knowledge of the structure and biology of AAV raise the 
expectations of dramatic improvement in AAV vector technology in the near future. 
The ultimate goal of all these attempts will be the generation of a recombinant AAV 
vector, which allows gene delivery exclusively to the desired cells or tissue, thereby widening 
the therapeutic window of this vector for clinical application. 
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ABBREVIATIONS
aa amino acid 
AAV adeno-associated virus, specifically 
  adeno-associated virus type 2 
AAVS1 AAV integration site 1  
 (located in human chromosome 19) 
Ab antibody 
Ad adenovirus 
AFM atomic force microscopy 
 
Amino acids: 
A (Ala) alanine 
C (Cys) cysteine 
D (Asp) aspartate 
E (Glu) glutamate 
F (Phe) phenylalanine 
G (Gly) glycine 
H (His) histidine 
I (Ile) isoleucine 
K (Lys) lysine 
L (Leu) leucine 
M (Met) methionine 
N (Asn) asparagine 
P (Pro) proline 
Q (Gln) glutamine 
R (Arg) arginine 
S (Ser) serine 
T (Thr) threonine 
V (Val) valine 
W (Trp) tryptophan 
Y (Tyr) tyrosine 
 
Bases:  
A adenin 
C cytosin 
G guanin 
T thymin 
 
 
B19 B19 human parvovirus 
bp base pair  
BSA bovine serum albumin 
Cap capsid protein  
cDNA complementary DNA 
ch chromosome 
CLL chronic lymphocytic leukemia 
CMV cytomegalovirus 
CPV canine parvovirus 
CTL cytotoxic T-lymphocyte 
Cy3, Cy5 indocarbocyanine dyes 
Da Dalton 
DMEM Dulbecco's Modified Eagle Medium 
e.g. for example (Lat.: exempli gratia) 
ELISA enzyme-linked immunosorbent 
assay 
FACS fluorescence-activated cell sorting  
FCS fetal calf serum 
FGFR fibroblast growth factor receptor 1 
Fig.  figure 
FISH fluorescence in situ hybridization 
FITC fluorescein isothiocyanate 
FPV feline panleukopenia virus 
GFP green fluorescence protein 
Gy Gray 
h hour 
HA hemagglutinin 
HSPG heparan sulfate proteoglycan 
i.e. that is (Lat.: id est) 
i.m. intra muscular 
ITR inverted terminal repeat 
kb kilobases 
Kd dissociation constant 
mAb monoclonal antibody 
MHC major histocompatibility complex 
min minute 
MOI multiplicity of infection 
NPC nuclear pore complex 
134 Abbreviation  
nt nucleotide 
ori origin of replication  
ORF open reading frame 
PLL poly-L-lysine 
rAAV recombinant AAV 
RBS Rep binding site 
Rep viral regulatory protein 
rpm rounds per minute  
RT room temperature  
SDS sodium dodecyl sulfate  
Stav streptavidin 
Stpl Streptavidin linked to polylysine 
T triangulation number  
TRS terminal resolution site 
VP viral protein (AAV capsid protein) 
wtAAV wild-type AAV 
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